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1. INTRODUCTION 
 
Thymus has been appreciated for its culinary properties already for hundreds of 
years. Its role as an organ required for the induction and maintenance of central 
tolerance however, has been acknowledged for just over half a century. Up until 
the early 1960s the thymus was thought to be a redundant organ. The fact that the 
thymus involutes and almost disappears in aged individuals only seemed to justify 
those convinced of the organ’s vestigiality. Although the thymus was known to be 
filled with lymphocytes, at best it was thought to serve as their graveyard. 
While working as a PhD student in a shack near London, Jacques Miller dis-
covered that severe autoimmune disorders develop in neonatally thymectomized 
mice – an effect not witnessed in mice thymectomized as adults. When his 
groundbreaking paper was published in 1961, Jacques Miller was met with be-
wilderment, as only a few leading scientists of the era believed the thymus to 
have a major function at all, lest to say, to be pivotal for the development of 
central tolerance. 
Today we know that the thymus provides a unique microenvironment for the 
stepwise maturation of thymocytes that give rise to peripheral T cell popu-
lations. The main populations indicated in influencing thymocyte maturation are 
thymic epithelial cells (TEC) in the cortex (cTEC) and medulla (mTEC). A 
proportion of mTEC expresses a transcription factor Autoimmune Regulator 
(Aire) which has been shown to be crucial for the negative selection of auto-
reactive thymocytes and induction of central tolerance. Mutations in the Aire 
gene cause a rare multiorgan autoimmune disorder named autoimmune poly-
endocrine syndrome 1 (APS1 or APECED). Although widely accepted as a 
pivotal protein in central tolerance induction, relatively little is known how the 
highly specific expression of Aire is regulated on transcriptional level. 
Immune tolerance induction is required to avoid immune responses towards 
self-antigens but it also plays a central role in mammalian reproduction. Preg-
nancy in mammals requires substantial reorganization of the maternal peripheral 
immune system to allow for the normal development of the semiallogenic  
fetus. Aside from the general thymic involution occurring during pregnancy, 
pregnancy-related effects on the thymic stromal cells have, by and large, re-
mained an unstudied subject in reproductive immunology. 
In multiple cell-types of the peripheral immune system the transcriptional 
changes taking place during their activation require the expression of Interferon 
regulatory factor 4 (Irf4). These include the cells involved in pathogen clearance 
as well as cells responsible for peripheral tolerance induction towards self- and 
foreign antigens. Despite being a well-known factor in peripheral immune 
homeostasis, it has not been studied in the context of central tolerance. 
Current thesis is focused on the transcriptional mechanisms involved in 
thymic epithelial cell function. We characterize the role of the conserved non-
coding sequence 1 (CNS1) in Aire induction, study the transcriptional changes 
taking place in thymic stroma during pregnancy-related thymic involution and 
dissect the role of Irf4 in TEC function. 
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2. REVIEW OF THE LITERATURE 
 
2.1.  Central and peripheral tolerance of the immune system 
 
A functional immune system is capable of protecting and clearing the host from 
invading pathogens and maintaining immune tolerance towards autologous and 
beneficial or benign foreign antigens. Immune tolerance is divided into central 
and peripheral tolerance depending on the time and site of induction. The two 
sites of central tolerance induction in mammals are the bone marrow for 
maturing B cells and the thymus for maturing T cells (Kyewski & Klein 2006). 
Peripheral tolerance induction occurs mainly in secondary lymph organs and 
mucosal tissues and concentrates on mature autoreactive B and T lymphocytes 
that have escaped central tolerance and on lymphocytes targeting antigens 
derived from the gut or from a developing fetus. As a result of central and peri-
pheral tolerance induction, auto-reactive lymphocytes are either deleted or 
differentiated into regulatory cells suppressing immune responses to the specific 
antigen (Plitas & Rudensky 2016, Rosenberg et al. 2016). 
 
 
2.2.  Thymus, its formation and thymic epithelial cells 
 
Thymus is a two-lobed organ positioned in the thoracic cavity anterior to the 
heart and is indispensable for the development of thymocytes and tolerance 
induction. In size it is proportionally the largest during infancy but starts to 
involute at puberty. In aged mammals most of the thymic tissue involutes and is 
replaced with connective and fatty tissue. In addition to age-related decrease in 
thymic size and T cell production, temporary thymic involution also takes place 
during infections and pregnancy after which the thymus restores to its age-
befitting size (Ansari & Liu 2017). 
Thymus is a primary lymphoid organ that arises from the third pharyngeal 
pouch at around embryonic day 10 or 11 in mice. In humans the thymic domain 
is evident by week 6 of gestation (Vaidya et al. 2016). The development of 
thymic tissue into organized outer cortex and inner medulla depends on the 
transcription factor Forkhead box N1 (Foxn1) (Takahama et al. 2017). A single 
base pair mutation in Foxn1 is responsible for the athymic and hairless pheno-
type of the nude mouse (Vaidya et al. 2016). 
The adult thymus contains thymic epithelial progenitor cells (TEPC) (Bleul 
et al. 2006) able to give rise to the main populations of TEC. TEPC population 
is most likely to reside  in the thymic cortico-medullary junction (CMJ), how-
ever the markers defining this rare population have not been agreed on. Sca1, 
Dec205 and Plet1 have all been suggested to distinguish TEPC from diffe-
rentiated TEC (Abramson & Anderson 2017). TEPC further differentiate into 
cTEC and mTEC that have distinct roles in promoting thymocyte differentiation 
(Takahama et al. 2017). cTEC are responsible for the early stages of thymocyte 
maturation up until the positive and negative selection of CD4+CD8+ double 
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positive (DP) cells. They express several molecules indicated in early thymo-
cyte differentiation and maturation, such as β5t (a thymoproteasome subunit), 
Dll4 (Delta-like 4), Kitl (Kit-ligand), IL7 (Interleukin 7) and Cd83 (Takahama 
et al. 2017) (discussed in detail in the next chapter). mTEC are responsible for 
the negative selection of autoreactive thymocytes and the generation of a sub-
population of T cells called regulatory T cells (Treg). Based on major histo-
compatibility complex class II (MHCII) and CD80 surface expression, mTEC 
can further be divided into mTEClo (CD80low MHCIIlow) and the more mature 
Ulex europeaus agglutinin 1 (UEA1) positive mTEChi (CD80hi MHCIIhi). The 
expression of Aire (Autoimmune regulator) in mTEChi has been shown to be 
crucial in the transcriptional activation of tissue specific antigen (TSA) required 
for thymic negative selection and thereby central tolerance induction (Anderson 
et al. 2002). 
cTEC differentiation relies mainly on the expression of Foxn1 and its target 
genes although arrest in a very early stage of thymocyte development has been 
shown to result in a disorganized cortex and cTEC arrested in an immature 
stage (Takahama et al. 2017). mTEC differentiation however, is dependent on 
external signaling from maturing thymocytes (Ohigashi et al. 2016). Positively 
selected thymocytes produce various tumor necrosis factor superfamily 
(TNFSF) members that have been shown to regulate mTEC maturation. Mice 
deficient in receptor activator of nuclear factor κB (RANK) on TEC or its 
corresponding ligand (RANKL) produced by CD4+ single positive (SP) thymo-
cytes have a significantly decreased mTEChi population and develop no Aire-
expressing cells (Rossi et al. 2007, Akiyama et al. 2008, Hikosaka et al. 2008). 
CD40L and lymphotoxin β (LTβ) produced by thymocytes have also been 
indicated in TEC differentiation. Both CD40-KO and LTβR-KO mice show 
aberrant mTEC maturation profiles, but combining either deficiency with a 
RANK-deficient background results in a phenotype virtually lacking mTEChi 
and Aire-expressing cells (Akiyama et al. 2008, Mouri et al. 2011). mTEChi 
cells have been shown to differentiate past the Aire-expressing stage and lose 
the expression of MHCII, CD80 and both Aire-dependent and independent TSA 
expression (Yano et al. 2008, Nishikawa et al. 2010, Wang et al. 2012). 
Eventually these post-Aire mTEClo differentiate into structures called Hassall’s 
corpuscles that express keratinocyte-specific antigens such as desmogleins 
(Dsg), keratins (Krt) and involucrin (Ivl).  
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Figure 1. Differentiation of thymic epithelial cells. The differentiation of early cortical 
thymic epithelial cells (cTEC) from the undefined thymic epithelial progenitor cell 
(TEPC) depends on unidentified signals (?). This differentiation is likely to take place in 
the cortico-medullary junction (CMJ), but is presently unknown. Further differentiation 
depends on unknown signals from early CD4-CD8- double-negative (DN) thymocytes. 
cTEC express multiple proteins facilitating early thymocyte differentiation and positive 
selection of the CD4+CD8+ double-positive population. Medullary TEC (mTEC) 
maturation following the mTEClo stage requires external signaling from CD4+ single 
positive (CD4+ SP) thymocytes (written in blue). mTEChi is the main population 
responsible for the negative selection and central tolerance induction as they express a 
vast array of tissue specific antigens (TSA). In later stages mTEChi lose TSA and Aire 
expression and eventually accumulate into Hassall’s corpuscles expressing keratinocyte 
TSA. MHC – major histocompatibility complex; β5t – thymoproteasome subunit, Dll4 – 
delta-like ligand 4, Kitl – Kit- ligand, IL7 – interleukin 7, RANK (L) – (ligand of) 
receptor activator of nuclear factor κB, LTβ – lymphotoxin beta, Aire – Autoimmune 
regulator, UEA1 – Ulex europeaus agglutinin 1, Dsg – desmogleins, Ivl – involucrin; 
Krt – keratins including Krt6, Krt10 etc. 
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2.3.  Thymocyte maturation 
 
By far the largest populations of cells in the thymus are thymocytes in different 
maturation stages (>95%). These stages range from thymic lymphoid pro-
genitors (TLP) to mature naïve single positive (SP) CD4+ T-helper (Th) or 
regulatory T cells (Tregs); and CD8+ cytotoxic T cells (CTL) (Figure 2). The 
recruitment of TLP to the embryonic thymus depends on Notch1 and several 
CC-chemokine receptors (Ccr) such as Ccr7, Ccr9 and CXC-chemokine 
receptor 4 (Cxcr4), which direct the cells towards high gradients of Ccl19, 
Ccl21 expressed by mTEC and Ccl25 and Cxcl12 expressed by cTEC and fibro-
blasts (Calderón & Boehm 2011, Takahama et al. 2017)  
TLP enter the thymus at the CMJ as CD4-CD8- double negative (DN) cells 
and relocate to the subcapsular cortex (Takahama 2006). IL7 and Kitl produced 
by both thymic fibroblasts and cTEC promote thymocyte survival and 
proliferation at these early stages (Gray et al. 2007b, Takahama et al. 2017). 
Separate DN stages are identified based on the expression of CD25 and CD44. 
Following the upregulation of CD25 in late DN1, cells commit to T cell lineage 
in DN2 stage (CD25+CD44+). Only thymocytes that succeed in the in-frame 
rearrangement of the gene encoding the T cell receptor (TCR) beta-chain and 
express the pre-TCR in DN3 (CD25+CD44-) enter the proliferating DN4 stage 
(CD25-CD44-). These cells give rise to the CD4+CD8+ DP thymocyte 
population via a cycling immature CD8+ intermediate SP cell population 
(Crompton et al. 2007). 
During cortical positive and negative selection DP thymocytes migrate 
towards the medulla and interact with cTEC and dendritic cells (DC) that 
present ubiquitous and serum-derived self-antigens on their cell surface (Klein 
et al. 2014). cTEC promote both the CD4+ and CD8+ SP thymocyte lineages by 
presenting MHC-associated self-peptides to newly formed DP thymocytes. 
Foxn1-induced thymoproteasome component β5t expressed specifically by 
cTEC is required for the processing of self-peptides loaded to MHCI thus 
influencing the CD8+ T cell differentiation (Uddin et al. 2017). cTEC-specific 
expression of CD83 on the other hand regulates the stability of MHCII mole-
cules on cTEC surfaces and is required for CD4+ thymocyte positive selection 
(Liu et al. 2016, von Rohrscheidt et al. 2016). A vast majority of TCR clones 
fail to interact with the self-MHC at all and die by neglect or activate TCR-
signaling in response to MHC-associated ubiquitous peptides presented on 
cTEC and DC which at this stage results in apoptosis. As a result, only a 
fraction of the produced DP thymocytes become SP and enter the thymic 
medulla in a Ccr7-dependent manner (Takahama 2006, Klein et al. 2014) 
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Figure 2. Intrathymic differentiation of T cell progenitors. Thymic lymphoid pro-
genitors enter the thymus in the cortico-medullary junction (CMJ) and migrate towards 
the subcapsular cortex as CD4-CD8- double negative (DN1-4) cells. Migration is 
dependent on chemokines (written in blue) secreted by cortical thymic epithelial cells 
(cTEC) and fibroblasts. Following the DN-stages proliferating CD8+ intermediate 
(CD8int) cells mature into CD4+CD8+ double positive T cell receptor-expressing cells 
(TCRhiDP). These cells are positively and negatively selected by cTEC and dendritic 
cells (DC). Positively selected CD4+ or CD8+ single positive (CD4+ SP and CD8+ SP, 
respectively) migrate towards the medulla and are negatively selected by medullary 
TEC (mTEC) and DC. Autoreactive cells are either removed, or at least in the CD4+ T 
cell lineage, central tolerance mechanisms can also differentiate them into Treg (tTreg). 
Negative selection ideally results in a mature naïve T cell pool not reactive to self and 
consists of naïve cytotoxic T cells (CTL) and helper T cells (Th) from the CD8+ SP and 
CD4+ lineages, respectively. MHC – major histocompatibility complex; Ag – antigen. 
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Thymic medulla is crucial in the selection of immunocompetent thymocytes. 
Medullary antigen-presenting cells (APC) including mTEC, DC and B cells 
present self-antigens to CD4+ or CD8+ SP thymocytes in the context of MHCI 
or MHCII in a process called negative selection (Takahama 2006, Klein et al. 
2014, Yamano et al. 2015). The main population responsible for negative 
selection is the mTEC (Klein et al. 2014). Whereas cTEC are thought to present 
ubiquitous antigens, mTEChi harbor a unique ability to express most of the TSA 
genes and proteins present in the genome (Sansom et al. 2014) Peptides from 
the encoded TSA are presented in the context of MHC to allow elimination of 
the possible pathogenicity of autoreactive thymocytes (Takahama 2006). If a 
thymocyte has a TCR that does not recognize any presented antigen as foreign, 
it will be considered safe for self and is allowed to exit to the periphery 
(Takahama 2006). Nolens volens, the random rearrangement occurring in the 
TCR locus results in thymocytes with high-affinity TCRs specific for self-anti-
gens. These cells, should they escape negative selection, can potentially cause 
autoimmunity in the periphery. Autoreactive thymocytes and peripheral T cells 
do exist in healthy individuals, but both central and peripheral tolerance main-
taining mechanisms exist that render the autoreactive cell anergic, delete it or 
differentiate it into a Treg (Xing & Hogquist 2012, Plitas & Rudensky 2016). 
 
 
2.3.1.  Regulatory T cells 
 
The path from the initial phenotypic description of a CD4+ T cell population 
with immunosuppressive capacity to the general acceptance of the existence and 
importance of Tregs took nearly two decades. In 1982 a paper was published 
showing that the transfer of sorted splenic CD4+CD90+ (Lyt1+Thy-1+) cells to 
neonatally thymectomized female mice protected them from the development of 
oophoritis (Sakaguchi et al. 1982). Years later it was found that the adoptive 
transfer of a subset of CD4+ T cells expressing high levels of CD25 (IL2Rα) but 
not CD25- cells to athymic mice suppresses the development of autoimmune 
diseases (Sakaguchi et al. 1995). It was only in 2000, when transcription factor 
forkhead box protein 3 (Foxp3) was found to be specifically expressed in 
CD4+CD25+ T cells, that Tregs were truly acknowledged to be a separate T cell 
subpopulation (Benoist & Mathis 2012). The FOXP3 gene is located in the X-
chromosome and was found to be mutated in IPEX (immune dysfunction, poly-
endocrinopathy, and enteropathy, X-linked) (Chatila et al. 2000), a rare disorder 
where male patients are affected by multiorgan autoimmunity (Benoist & 
Mathis 2012). In mice, both the germline deletion and conditional deletion of 
Foxp3 in T cells result in a phenotypically identical T cell dependent severe 
autoimmunity (Fontenot et al. 2005). 
Tregs are MHCII restricted CD4+ T cells that can be divided into two major 
subpopulations depending on the site of tolerance induction: those induced by 
central tolerance are of thymic origin (tTreg) and peripherally induced Tregs 
(pTreg) emerge mostly form mucosal tissues and are induced by peripheral 
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tolerance (Lin et al. 2013). tTregs develop in thymic medulla from autoreactive 
αβ T cells that for a long time were thought to be rendered anergic and deleted 
after TCR-activation during negative selection (Benoist & Mathis 2012). In fact 
apoptosis or deletion of autoreactive thymocytes has recently been shown to be 
far less common than previously thought (Malchow et al. 2016) and rather these 
autoreactive cells differentiate into Treg. The stromal cells mostly indicated in 
tTreg differentiation are mTEChi that present a vast library of self-peptides on 
their surface (Anderson et al. 2002, Klein et al. 2014). Similarly to Th and CTL, 
tTreg differentiation requires additional signaling from costimulatory molecules 
such as CD40, CD80 and CD86 on mTEChi (Williams et al. 2014). However, 
aside from Aire, little is known about other mTEC-specific factors that regulate 
tTreg differentiation in the thymus. pTregs differentiate mainly in the gut from 
peripheral Foxp3- Th upon exposure to antigenic stimulation under tolerogenic 
conditions: encounter of a foreign tolerizing antigen or a self-antigen, chronic 
and/or suboptimal stimulation by agonist peptide etc. (Benoist & Mathis 2012). 
If an autoreactive Th meets its specific auto-antigen in the periphery it is usually 
rendered anergic. Recent evidence shows that anergy in peripheral autoreactive 
Th does not necessarily lead to deletion, but could actually be an important 
intermediate stage required for pTreg differentiation (Kalekar et al. 2016).   
Although not yet elaborated on as to why, central and peripheral mecha-
nisms exist to restrict Treg differentiation. Tregs in the thymus of a 5-week old 
mouse are a roughly 1:1 mixture of differentiating tTregs and Tregs that have 
recirculated back to the thymus and the proportion of new tTregs declines with 
age (Thiault et al. 2015). Although the mechanism is still unclear, recirculating 
Tregs restrain the development of thymic Treg precursors (Thiault et al. 2015). 
In T cell-mediated colitis the peripheral induction of Tregs, Ccr9 expression 
appears to have a negative effect on pTreg differentiation, as Ccr9-KO mice ex-
hibit an enlarged Treg population in the spleen and mesenteric lymph nodes 
(Evans-Marin et al. 2015). 
Although the existence of both tTreg and pTreg is not disputed, the dis-
crimination between the two subtypes is a more controversial issue. The ex-
pression of Helios and Neuropilin 1 (Nrp1) in steady state has been suggested to 
differentiate tTregs from pTregs (Sugimoto et al. 2006, Round & Mazmanian 
2010, Yadav et al. 2012). Both markers have separately been shown to be up-
regulated in activated pTreg, therefore the use of either marker alone as a tTreg 
marker is controversial (Lin et al. 2013, Szurek et al. 2015). A review dis-
cussing these issues (Lin et al. 2013) suggests that until more robust markers are 
identified, tTregs should be defined as Foxp3+ cells co-expressing Nrp1 and 
Helios. 
Both tTreg and pTreg present imperative populations in the maintenance of 
peripheral tolerance and immune homeostasis. tTregs are mainly thought to 
induce peripheral tolerance to self-antigens and pTregs predominantly induce 
tolerance to foreign antigens in the mucosal tissues (Plitas & Rudensky 2016). 
Antigens for pTreg additionally include allergens, antigens from food and 
microbiota and paternal alloantigens during fetal development (Samstein et al. 
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2012, Plitas & Rudensky 2016, Kalekar & Mueller 2017). There are several 
mechanisms by which Tregs as a bulk population suppress the activation of Th 
cells and CTL. Ectoenzymes CD39 and CD73 expressed on Treg mediate the 
conversion of extracellular ATP to adenosine, which directly inhibits the 
proliferation of effector T cells and suppresses the activity of DCs and myeloid 
cells (Plitas & Rudensky 2016). Other molecules expressed by Treg to directly 
suppress T cell activation include Il10, TGFβ and programmed death 1 receptor 
(PD-1) and ligand (PD-1L) (La Rocca et al. 2014). Cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) expressed on Treg can have a dual effect on 
APC that is presenting a TSA. First, it can induce DC to express the enzyme 
indoleamine 2, 3-dioxygenase, which catabolizes conversion of tryptophan to 
kynurenine that is toxic to T cells (Grohmann et al. 2002). Secondly CTLA-4 
has been shown to downregulate the surface expression of CD80 and CD86 on 
DC thus inhibiting the costimulatory signal required for T cell activation (Wing 
et al. 2008). IL2 has been shown to be critical for Treg differentiation and 
function (Benoist & Mathis 2012), however recent evidence suggests that 
responsiveness to IL2 is required only for Treg mediated suppression of 
autoreactive CTL, but is dispensable for regulating Th activation (Chinen et al. 
2016). 
 
 
2.4.  Aire 
 
2.4.1.  AIRE gene and protein 
 
The AIRE gene was cloned by two separate groups in 1997 (Consortium 1997, 
Nagamine et al. 1997) as a gene mutated in APS1. Aside from mTEC, where its 
expression was first described (Heino et al. 1999), mouse Aire has been found 
to be expressed in rare peripheral APC and testicular germ cells, and most 
recently in thymic B cells (Schaller et al. 2008, Yamano et al. 2015). Aire 
expression in mTEC is required for the induction and maintenance of thymic 
central tolerance and thymic Aire-positive B cells are thought to provide addi-
tional level of tolerance induction, however the role of Aire expression in 
peripheral cells is less clear (Anderson et al. 2002, Gardner et al. 2008, Yamano 
et al. 2015, Abramson & Husebye 2016). 
The AIRE gene sequence and the functional domains of the encoded protein 
are highly conserved (Saltis et al. 2008). The human AIRE gene is located in 
chromosome 21q22.3 and it codes for a 545 aa protein (Consortium 1997, 
Nagamine et al. 1997). The functional domains of the AIRE protein include a 
N-terminal caspase-recruitment domain (CARD), nuclear localization sequence 
(NLS), SAND (SP100, AIRE1, NucP41/P75 and DEAF1) domain, two plant 
homeodomain zinc fingers (PHD1 and PHD2), a proline-rich region (PRR) and 
four leucine rich regions (Peterson et al. 2008). On cellular level AIRE has a 
specific nuclear location where it forms structures called nuclear dots (Björses 
et al. 1999, Heino et al. 1999). The formation of these dots depends on the N-
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terminal CARD-domain of the AIRE protein (Ferguson et al. 2008). Mutations 
in the conserved amino acids of the CARD domain have been shown to disrupt 
the homo-oligomerization of Aire and dimerization of Aire with other factors 
such as CBP and P-TEFb resulting in the loss of nuclear dots and AIRE-
mediated transcription (Peterson et al. 2008). The SAND domain in AIRE is 
required to interact with ATF7ip/MBD1 complex to locate to Aire-responsive 
genes (Waterfield et al. 2014). The two PHD-fingers of the AIRE protein have 
distinct roles in AIRE-mediated transcriptional activation. First of the two PHD-
fingers binds the unmethylated lysine 4 of histone 3 (H3K4me0) near AIRE 
target genes (Koh et al. 2008, Org et al. 2008), whereas the second PHD-finger 
interacts with several AIRE-interacting proteins indicated in DNA-damage 
response (DDR) (Abramson et al. 2010, Yang et al. 2013). The LXXLL 
nuclear-receptor-binding motifs (X for any amino acid) present in the AIRE 
protein are also likely to be involved in transcriptional activation (Savkur & 
Burris 2004). 
 
 
 
 
Figure 3. The structural domains of the AIRE protein and their general function. CARD 
(caspase recruitment domain); NLS (nuclear localization signal); SAND (SP100, 
AIRE1, NucP41/P75 and DEAF1 domain), PHD (plant homeodomain); PRR (proline-
rich region). CBP – CREB-binding protein; PTEFb – positive transcription elongation 
factor b; H3K4me0 – unmethylated lysine 4 of histone 3; DDR – DNA-damage 
response; TA – transcription activation; ATF7ip/MBD1 – activating transcription factor 
7–interacting protein/ methyl-CpG binding domain protein 1. 
 
 
Over a hundred APS1-related mutations have been found in the AIRE locus. 
APS1 is a rare autoimmune disorder characterized by a clinical triad – chronic 
mucocutaneous candidiasis, hypoparathyroidism and Addison’s disease (adrenal 
insufficiency) (Abramson & Husebye 2016). For diagnosis, two of the three 
components must develop but several other autoimmune complications may 
also occur in APS1 patients such as type 1 diabetes, ovarian failure, vitiligo etc. 
The disease-causing mutations have been identified throughout the AIRE gene, 
but even siblings having the same mutation can develop different clinical mani-
festations (Abramson & Husebye 2016). APS1-patients can also develop auto-
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antibodies towards up to a hundred self-proteins including target tissue enzymes 
and immune modulators such as Th17-associated interleukins IL17 and IL22 
and interferons (Kisand et al. 2008, Kisand et al. 2010, Meyer et al. 2016). 
Surprisingly, the occurrence of high-titer interferon autoantibodies correlates 
with lower incidence of type 1 diabetes in APS1-patients (Meyer et al. 2016). 
Recent data demonstrate that certain mono-allelic mutations in AIRE can give 
rise to “non-classical APS-1”, characterized by a broad scale of organ-specific 
autoimmune disorders, which typically do not match the diagnostic criteria of 
classical APS-1 (Oftedal et al. 2015), making disease-inflicting AIRE-mutations 
much more common than previously though 
 
 
2.4.2. Transcriptional regulation of Aire in mTEC 
 
In the thymic epithelial compartment Aire expression is limited to the mTEChi 
population that is positive for the co-stimulatory markers CD80, CD86 and 
CD40, and that has high levels of MHCII expression (Heino et al. 1999, Zuklys 
et al. 2000, Derbinski et al. 2001). Aire expression is induced only for a few 
days (Wang et al. 2012) in response to RANK-signaling (Akiyama et al. 2008, 
Hikosaka et al. 2008, Irla et al. 2008). Downstream of RANK ligation both the 
classical and alternative nuclear factor kappa B (NF-κB) pathways are activated. 
The transcriptional activation of genes depending on the classical NF-κB path-
way involves the assembly of the IKK-α, IKK-β, and IKK-γ protein complexes 
and consequent nuclear translocation of the RelA/p50. The prerequisite for 
genes activated by the alternative NF-κB is the phosphorylation of IKK-α by 
NF-κB inducing kinase (NIK) and nuclear translocation of the RelB/p52 
complex (Akiyama et al. 2012). Although the disruption of either NF-κB path-
way results in aberrant TEC-profiles, decreased Aire expression or both 
(Akiyama et al. 2012), the studies concerning NF-κB in mTEC have been 
unable to distinguish between the effects these pathways have on mTEC 
maturation and Aire expression. The initiation of AIRE transcription requires 
hypomethylation of a CpG island in AIRE promoter that is heavily methylated 
in cells outside the TEC lineage (Murumägi et al. 2003, Kont et al. 2011). 
Transcription factors from the E26 transformation-specific family have been 
shown to bind to the regulatory elements of AIRE proximal promoter 
(Murumägi et al. 2006). Additionally, the Aire distal promoter contains a highly 
conserved region of 90 nucleotides suggested to have a role in regulating Aire 
expression (Blechschmidt et al. 1999). Recently AIRE expression was shown to 
be controlled by multiple transcription factors including Irf4, Irf8, Tbx21, Tcf7 
and Ctcfl (Herzig et al. 2017). Adding another layer to the tight control of Aire 
expression is the discovery that Jmjd6, a lysyl-hydroxylase, is required for Aire 
protein expression (Yanagihara et al. 2015). Aire mRNA expression was not 
altered in Jmjd6-deficiency, but due to inefficient splicing of the intron 2 of the 
Aire mRNA, mature Aire protein levels were severely decreased and mice with 
transplanted Jmjd6-deficient thymus developed multiorgan autoimmunity. 
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2.4.3. Aire-dependent promiscuous gene expression 
 
Each tissue in a body has its own specific gene expression profile. In addition to 
ubiquitously expressed genes, the genes encoding TSA are also expressed and 
are specific for a given tissue. mTEChi is a unique cell population as it expresses 
thousands of TSA and more than 3000 different genes are expressed in an Aire-
dependent manner (Sansom et al. 2014). This process is called promiscuous 
(ectopic) gene expression (PGE). During negative selection, mTEChi present 
peptides in combination with MHC molecules on the cell surface to identify 
autoreactive thymocytes (Klein et al. 2014). In mTEC the genes that encode 
TSAs often bear epigenetic marks inherent to transcriptionally silenced 
chromatin such as H3K4me0 and H3K27me3 (Org et al. 2009, Sansom et al. 
2014). The PHD1 of AIRE protein acts as a histone code reader specifically 
binding to H3K4me0 to activate the expression of silent genes (Koh et al. 2008, 
Org et al. 2008). Multiple proteins have been identified that interact with AIRE 
in TSA expression, several of which have a role in DDR [reviewed in 
(Abramson & Husebye 2016)]. Examples of Aire-induced TSA in mTEChi 
include Insulin 2 (Ins2) which in the periphery is restricted to pancreatic beta 
cells and Salivary protein1 (Spt1) restricted to salivary and lacrimal glands 
(Derbinski et al. 2005, Kont et al. 2008, Org et al. 2008). Failure to induce 
sufficient levels of Ins2 in mTEChi results in the escape of pro-insulin specific 
autoreactive T cells (Chentoufi & Polychronakos 2002). In double-transgenic 
mice with hen egg lysosome specific T cells that had hen egg lysosome ex-
pressed as a neo-self antigen under the control of the rat insulin promoter, Aire-
deficiency results in almost a complete failure of hen egg lysosome-specific 
autoreactive thymocyte deletion often accompanied by fatal neonatal diabetes 
(Liston et al. 2003, Liston et al. 2004). Recent evidence suggests that rather than 
deleting thymocytes with self-antigen specific TCR, Aire expression in mTEChi 
is required to promote the differentiation of Tregs from these autoreactive 
thymocytes (Malchow et al. 2016). 
Aire also influences the expression of genes involved in thymocyte and DC 
migration and TEC differentiation. Aire-KO mice exhibit delayed medullary 
migration of CD4+ SP cells due to decreases in the mTEC specific expression of 
ligands for Ccr4 (Ccl5, Ccl17, Ccl22) and Ccr7 (Ccl19 and Ccl21) (Laan et al. 
2009). Aire regulates the expression of Xcl1, which is required for medullary 
accumulation of thymic DC (Lei et al. 2011). Xcl1-KO mice have a normal 
distribution of thymic DC subpopulations, but they fail to migrate to the 
medulla and promote tTreg differentiation, resulting in decreased tTreg numbers 
and thymocytes that elicit inflammation when transferred into nude mice (Lei et 
al. 2011). Aire-KO mTEChi fail to differentiate into keratinocyte-like terminally 
differentiated cells. Instead, in Aire-KO mice, mTEC accumulate in the mTEChi 
stage and display aberrant expression of keratinocyte markers such as Dsg3, 
Krt6, Krt10 and Ivl (Yano et al. 2008, Wang et al. 2012). 
Although Aire is responsible for the induction of up to half of the genes in 
PGE, there are still thousands of TSA expressed in an Aire-independent manner 
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(Sansom et al. 2014). Recently, LTβR-dependent transcription factor Fezf2 was 
shown to regulate the expression of a subset of Aire-independent TSA in TEC 
that are specific for peripheral tissues such as the lung and the liver. Fezf2-
deficiency results in peripheral autoimmunity in respective tissues as well as 
autoantibodies specific for lung, retina and skin (Takaba et al. 2015). 
 
 
2.5.  Pregnancy and tolerance 
 
From a purely immunological point of view the developing fetus represents a 
semiallogenic transplant that should be rejected by the host’s immune system. It 
has become clear that substantial changes take place in the peripheral immune 
system of women during pregnancy. One of the main cell population indicated 
in inducing tolerance towards the fetus is Treg that show an extensive growth in 
numbers in the peripheral blood and decidua during pregnancy (Aluvihare et al. 
2004, Arck & Hecher 2013). In mice pTregs specific for paternal antigens are 
induced in uterine draining lymph nodes upon encountering seminal plasma 
antigens and these cells accumulate to the uterus ready to suppress inflam-
matory reactions towards paternal antigens before the blastocyst implants 
(Aluvihare et al. 2004, Ruocco et al. 2014, Clark 2016). Pregnant mice, who 
specifically lack pTreg, but not tTreg, display increased embryonic resorption 
and immune cell infiltrations in the arteries supplying blood to the endometrium 
(Samstein et al. 2012).  
Peripheral immune system and its role in tolerance induction are rather well 
described. However, relatively little is known about the effects pregnancy has 
on central tolerance and vice versa – what role does the central tolerance have in 
pregnancy-related tolerance induction. Amelioration of several autoimmune 
diseases, including rheumatoid arthritis and multiple sclerosis has been ob-
served during human pregnancy, indicating that certain tTreg clones may 
become more prominent among the bulk Treg population (Arck & Hecher 
2013). One well-described effect that pregnancy inflicts on central tolerance is 
the temporary decrease in thymic volume (Chambers & Clarke 1979, 
Shinomiya et al. 1991). Thymic involution during pregnancy occurs in all the 
mammals examined and at least in pregnant mice lack of pregnancy-related 
thymic involution (PRTI) results in decreased fertility (Clarke & Kendall 1994, 
Tibbetts et al. 1999). During murine pregnancy serum progesterone level is 
upregulated and reaches plateau at mid-pregnancy (Chung et al. 2012). Pro-
gesterone signaling is at least partially responsible for PRTI and for the 
developmental arrest of DN1 thymocytes (Tibbetts et al. 1999). Estrogen serum 
levels peak at the third trimester (Chung et al. 2012) resulting in decreased 
thymocyte proliferation and thymic output at late stage pregnancy (Zoller et al. 
2007). Thymocyte differentiation and proliferation relies on signals received 
from thymic stromal cells (TEC, fibroblast, DC). Pregnancy is known to call 
forth certain phenotypic changes related to proliferation and phagocytic activity 
in these cells (Kendall & Clarke 2000), but pregnancy-related transcriptional 
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changes have not been described in the thymic stroma. In age-related thymic 
involution (ARTI), mTEC and cTEC have been shown to downregulate the 
expression of E2f3, a transcription factor critical for cell proliferation (Ki et al. 
2014). Additionally the expression of a Notch1 ligand Dll4 decreases in thymic 
stroma during aging. Thymic DC on the other hand increase the expression of 
proinflammatory molecules such as IL1, IL6 (Ki et al. 2014). Whether ARTI 
and PRTI share common traits remains to be determined.  
 
 
2.6.  Irf4 
 
2.6.1. Irf4 gene and protein 
 
In mammals the Interferon regulatory factor (IRF)-family consists of 9 members 
with a variety of functions in the immune system, metabolism, cancer and disease 
progression (Savitsky et al. 2010, Zhao et al. 2015). Irf4 was first identified in 
1992 as a co-factor for PU.1 that binds to the immunoglobulin κ 3’ enhancer 
(Pongubala et al. 1992). The Irf4 gene was cloned by two separate groups in 1995 
(Eisenbeis et al. 1995, Matsuyama et al. 1995) and the first in vivo study in 1997 
revealed that Irf4-KO mice completely lack germinal center B cells and antibody 
secreting plasma cells (Mittrücker et al. 1997). These initial studies identified Irf4 
as a lymphoid-specific transcription factor. Following publications have 
implicated Irf4 to be one of the key regulators of cell differentiation and function 
not only in other immune cells (Honma et al. 2005, Lehtonen et al. 2005, 
Mohapatra et al. 2015) but also in cells outside the immune system (Eguchi et al. 
2011, Nakashima & Haneji 2013, Praetorius et al. 2013, Guo et al. 2014) 
In human the IRF4 gene codes for a 450 aa protein that bears a 92% 
similarity with the mouse Irf4 (Grossman et al. 1996). As a transcriptional 
regulator, Irf4 is generally located in the nucleus (Brass et al. 1996) but can also 
be found in the cytoplasm (Negishi et al. 2005). Similarly to other IRF-proteins, 
Irf4 has a roughly 115 aa long N-terminal DNA-binding domain (DBD), that is 
characterized by five conserved tryptophan repeats that are separated by 10-18 
aa (Matsuyama et al. 1995). The DBD of all IRFs binds to conserved IFN-
stimulated response elements via its helix-loop-helix domain (Fujii et al. 1999). 
Within the DBD of Irf4 lies the NLS (Lau et al. 2000), which is required for Irf4 
translocation from cytoplasm following extracellular stimuli such as activation 
of macrophages (Mϕ) by LPS (Negishi et al. 2005). The C-terminal IRF-
association domain is required for forming homodimers (Ochiai et al. 2013) or 
heterodimers with other transcription factors such as Irf8 or PU.1 (Brass et al. 
1999, Lu et al. 2003). When binding IFN-stimulated response elements as a 
homodimer, the interactions between Irf4 and DNA are weak probably due to 
the C-terminal auto-inhibitory domain of Irf4 hampering the binding of the 
DBD (Brass et al. 1996). However, as a homodimer, Irf4 can repress the 
transcription of IFN-stimulated genes by dislocating other IRF-family members 
Irf1 and Irf2 (Brass et al. 1996, Yamagata et al. 1996). When binding DNA with 
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transcriptional co-activators such as PU.1, the avidity of Irf4 binding to DNA is 
increased as strong interactions are formed between the auto-inhibitory domain 
of Irf4 and the phosphorylated PEST domain of PU.1 (Pongubala et al. 1992, 
Brass et al. 1999). 
 
 
2.6.2. Transcriptional regulation of Irf4 in the immune system 
 
Although initially defined as a lymphoid lineage specific member of the IRF 
family (Eisenbeis et al. 1995, Matsuyama et al. 1995), Irf4 is expressed in 
several cell types of both innate and adaptive immune system (Nam & Lim 
2016) (Figure 4). Contrary to several other IRF-transcription factors that are 
induced by type I IFN-signaling, Irf4 activation in fact, results in the repression 
of IFN-stimulated genes (Brass et al. 1996, Yamagata et al. 1996). In immune 
cells Irf4 expression is activated cell-specifically by extracellular stimuli 
generally leading to the activation of the classical NF-κB pathway (Shaffer et al. 
2009). The Irf4 promoter binds several members of STAT and NF-κB in human 
monocytes differentiating into DC following antigen encounter, GM-CSF and 
IL4 co-stimulation or TNFα stimulation (Lehtonen et al. 2005). In T- and B 
lymphocytes Irf4 is induced during both maturation and activation. The most 
prominent cell-extrinsic signal leading to Irf4 induction in lymphocytes is the 
signaling downstream of their antigen binding receptors (TCR and BCR) and 
the consequent activation of c-Rel (Grumont & Gerondakis 2000). Additionally, 
IL4 and CD40 co-stimulation has been shown to upregulate Irf4 expression in B 
cells (Gupta et al. 1999). Alone, IL4-signaling can induce Irf4 in Mϕ (Honma et 
al. 2005) where its expression is further controlled by a histone demethylase 
Jmjd3 (Satoh et al. 2010).  
 
Figure 4. The induction and function of Irf4 in immune cells. Cell-specific extracellular 
(EC) signaling leads to the activation of the classical NF-κB, which in turn upregulates 
Irf4 expression. Cell-specific functions for Irf4 in peripheral dendritic cells (DC), 
macrophages (Mϕ) and in B and T cells. GM-CSF – granulocyte macrophage colony-
stimulating factor IL4 – interleukin 4, TNFα – tumor necrosis factor α; TCR – T cell 
receptor; BCR – B cell receptor; CSR – class switch recombination; Ab – antibody. 
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2.6.3. Irf4 in the innate immune system 
 
In mammals, the first immune cells to be activated upon encountering new 
pathogens originate from the innate immune system. The outcome of the 
infection depends on complex interactions between APCs and effector cells 
from both the innate and the more specific adaptive immune system. Several 
studies have shown that Irf4 functions as a key regulator of differentiation and 
function in several cell types with APC and/or effector capacity from both 
hands of the immune system [Figure 4 and reviewed in (Nam & Lim 2016)]. 
The majority of research concerning Irf4 in innate immunity has con-
centrated on its role in DC and Mϕ that phagocytose pathogens, infected or 
apoptotic cells, cell debris etc. Both these cell-types link innate and adaptive 
immune systems by presenting antigens to their lymphocytic counterparts 
(Savina & Amigorena 2007). 
Irf4 is induced in M2 Mϕ polarization and activates the expression of several 
M2 Mϕ marker genes required for pathogen phagocytosis (Satoh et al. 2010). 
Following peritoneal administration of chitin, a M2 polarizing agent, only 
eosinophil but not Mϕ recruitment was impaired in Irf4-KO mice. However, the 
expression of M2 Mϕ marker genes such as Arg1, MR and Ym1 was 
significantly downregulated in chitin induced Mϕ from Irf4-KO mice. Recently 
Irf4 was shown to control the development of a peritoneal monocyte-derived 
Mϕ population (Kim et al. 2016). Although the exact function of these Mϕ is yet 
unknown, they express high levels of MHCII and their differentiation was 
blocked by both Irf4-deficiency and antibiotic treatment, indicating that they 
might act as APC mediating signals between the microbiome and the immune 
system.  
In DC Irf4 is crucial for the function of the CD11b+ conventional DC and 
monocyte derived DC (Suzuki et al. 2004, Schlitzer et al. 2013). Both subtypes 
serve as potent APC for T lymphocytes and can promote both Th and CTL 
responses (Mildner & Jung 2014). As CD11b+ conventional DC are a hetero-
geneous group of cells, Irf4-deficiency only partially affects their function in 
certain tissues (Mildner & Jung 2014). For instance, in cutaneous inflammation 
Irf4-deficient CD11b+ conventional DC fail to migrate into lymph nodes 
(Bajaña et al. 2012). Irf4 promotes the survival of mucosal CD11b+ con-
ventional DC and is required for IL23 production in steady state and upon 
fungal challenge (Schlitzer et al. 2013). In inflammation and fungal challenge, 
DC are capable of phagocytosis, but fail to upregulate MHCII expression and 
migration is obstructed by the lack of Irf4-dependent Ccr7 expression. 
Altogether the described Irf4-deficient CD11b+ conventional DC no longer act 
as APC and fail to promote Th17 and Th2 responses in disease. Irf4 is 
dispensable for CD11b+ conventional DC that cross-present antigens to CD8 T 
cells but in monocyte-derived DC, Irf4 is needed for these cells to differentiate 
into APC capable of cross-priming CD8 T cells (Briseño et al. 2016). 
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2.6.4. Irf4 in the adaptive immune system 
 
Studies have shown that in most B cell differentiation stages Irf4 functions 
redundantly with Irf8, but Irf4 is a crucial factor for the development of antigen-
presenting and antibody producing B cells (Mittrücker et al. 1997, Falini et al. 
2000, Lu et al. 2003, Klein et al. 2006). In the absence of both Irf4 and Irf8, 
early B cells fail to exit the cell cycle and consequently cannot differentiate into 
the immature B cell stage (Lu et al. 2003). Irf4 is also required for receptor 
editing of the Igκ and Igλ loci in bone marrow B cells that react to self-antigen 
(Pathak et al. 2008) indicating a role for Irf4 in B cell tolerance induction. 
In mature B cell stages the redundancy between Irf4 and Irf8 disappears as 
Irf4-deficiency, but not Irf8 deficiency, results in aberrant activation of mature 
B cells, germinal center formation and failure to commit to class switching (De 
Silva et al. 2012, Willis et al. 2014). Germinal center formation between mature 
B cells and follicular Th is diminished both in Irf4-KO mice and in mice where 
Irf4 is conditionally deleted in CD23-expressing mature B cells (Mittrücker et 
al. 1997, Willis et al. 2014). Irf4-dependent germinal center formation, how-
ever, is not intrinsic only to B cells as transferred Irf4-KO CD4 T cells in L. 
major infection model do not to upregulate Bcl6 and Icos and hence fail to 
differentiate into follicular Th cells (Bollig et al. 2012). 
Mature naïve B cells in peripheral lymphoid tissues express IgM and IgD as 
their BCR. The differentiation step during which antigen-stimulated B cells 
reorganize the constant region of the Ig heavy chain and acquire the ability to 
express other Ig molecules (e.g. IgG) is called class switch recombination 
(CSR) (Zan & Casali 2015). A key factor in this process is an enzyme AID 
(transcribed from Aicda – activation induced cytidine-deaminase), which 
introduces mutations into the Ig heavy chain locus. In addition to regulating 
Aicda in CSR following CD40 and IL4 stimulation, Irf4 together with Blimp1 
also controls the expression of Xbp1 which is required for plasma cell 
generation (Klein et al. 2006). In addition, the complex involving Irf4/8, PU.1 
and E47 is shown to regulate CIITA in B cells, rendering Irf4-deficient B cells 
incapable of presenting antigens (van der Stoep et al. 2004). 
Irf4 is required for the effector function of both Th and CTL, but in the 
thymus it has shown to be induced only in TCR-signaled CD69hi SP thymocyte 
(Cao et al. 2010, Nayar et al. 2012). However, both full Irf4-KO and CD4-
specific Irf4-conditional KO (cKO) have normal-sized thymi with WT-like 
distribution of thymocytes (Mittrücker et al. 1997, Nayar et al. 2012). This 
indicates that redundancy exists between Irf4 and (most likely) Irf8 in thymo-
cyte development as it does in early B lymphocyte development (Lu et al. 
2003). 
Although dispensable for the thymic development of T cells, Irf4 expression 
is an absolute necessity for most, if not all TCR-signaled peripheral Th and 
CTL populations (Huber & Lohoff 2014). The peripheral T cell pool consists of 
different Th-populations and Tregs from the CD4+ lineage and CTLs and 
cytokine-secreting Tc cells (Tc9 and Tc17, so far) from the CD8+ lineage 
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(Huber & Lohoff 2014). Irf4-deficiency in L. monocytogenes infection model 
results in impaired Th1 differentiation of the transferred Irf4-KO CD4+ T cells 
and decreased Ifnγ expression (Mahnke et al. 2016). Other groups carried out 
similar experiments with transferred Irf4-KO CD8+ T cells in viral and bacterial 
infections (Man et al. 2013, Yao et al. 2013) and found that Irf4-deficient CTLs 
fail to kill the infected cells and clear the infection despite acquiring an 
activated phenotype. In Th2 cells Irf4 upregulates GATA3 and Gfi1 required for 
Th2 differentiation and, along with Nfat factors stimulates IL4 expression (Nam 
& Lim 2016). Both the Th and CTL lineages have effector cells in human and 
mouse that express IL9 or IL17 (Th9, Th17 and Tc9, Tc17, respectively). As the 
expression of IL9 and IL17 is directly regulated by Irf4 in T cells (IL9 in mast 
and innate lymphoid cells as well), these subtypes fail to function as effector 
cells in Irf4-deficient conditions (Huber & Lohoff 2014, Nam & Lim 2016). 
The IL17-expressing subtypes Th17 and Tc17 have been indicated in multiple 
sclerosis (Huber et al. 2009, Burkett et al. 2015). The lack of either population 
in Irf4-KO mice, however, renders the mice resistant to experimental 
autoimmune encephalomyelitis in mouse model (Brüstle et al. 2007, Huber et 
al. 2013, Yang et al. 2015a). 
Perhaps the most drastic systemic effect of Irf4-deficiency on effector CD4+ 
T cells is seen in Treg, where Irf4 regulates the genes required to control Th2 
and Th1 responses (Zheng et al. 2009, Cretney et al. 2011). Treg-specific Irf4-
cKO mice develop a severe autoimmune phenotype soon after weaning and die 
as early as 3-4 months of age (Zheng et al. 2009). These mice have high levels 
of activated CD4+ T cells, aberrant Th2 responses and show high levels of 
serum IgG1 and IgE in response to IL4. Additionally, they develop severe 
autoimmune infiltrations in several tissues with notable plasma cell contents. 
 
 
2.6.5. Irf4 in cancer and other tissues 
 
In addition to orchestrating the responses to pathogens in multiple immune 
system cell types, Irf4 has a role in the pathogenesis of several conditions, most 
notably malignant tumors and hematopoietic cancers. Interestingly, only a few 
tumor-related mutations have been described for Irf4, rather its oncogenic 
capacity derives from anomalous expression. Recently a single nucleotide poly-
morphism was identified in intron 4 of Irf4 (Praetorius et al. 2013). This single 
nucleotide polymorphism lies in Irf4 enhancer and in addition to affecting 
pigmentation in humans (Praetorius et al. 2013) it is shown to either increase or 
decrease Irf4 expression in different hematopoietic cancers and reduce Irf4 
expression in melanoma (Gibbs et al. 2016). The oncogenic potential of IRF4 is 
best described in multiple myeloma, where BLIMP1 fails to downregulate MYC 
expression resulting in positive transcriptional feedback loop between the proto-
oncogene MYC and IRF4 (Shaffer et al. 2008). Thus the plasma cells in 
multiple myeloma become highly proliferating, but die following the suppres-
sion of IRF4 in vitro. 
30 
Outside the hematopoietic system Irf4 has, for instance, been shown to 
inhibit lipogenesis in adipocytes (Eguchi et al. 2011). In these cells Irf4 expres-
sion is induced only in the absence of insulin by FoxO1 to promote lipolysis 
and is quickly downregulated following feeding. Mice with adipocyte-specific 
Irf4-deficiency become cold-intolerant and gain significantly more weight on 
high-fat diet than WT mice. In bone tissue, Irf4 regulates the formation of 
osteoclasts in a RANKL-dependent manner (Nakashima & Haneji 2013). Mice 
that were injected with RANKL alone showed greater osteoclast formation and 
decreased bone mineral density compared to controls (mice injected with 
RANKL and RANK-inhibitor simvastatin). The group behind the study 
suggested that Irf4-dependent activation of Nfatc1 downstream of RANKL is 
required for osteoclast formation from bone Mϕ. Irf4 is expressed on a basal 
level in neurons, where it can be upregulated by ischemic stroke (Guo et al. 
2014). Irf4-deficient neurons fail to upregulate several genes such as FosB and 
Egr1 which are required for the neuron to survive the stroke. Neuron-specific 
Irf4 transgenic mice on the other hand develop milder lesions and lower 
neuronal apoptosis following a stroke. 
 
***** 
 
The induction of central tolerance depends on elaborate interactions between 
maturing T cells and thymic stromal cells. These interactions in turn depend on 
already activated transcriptional mechanisms in these cells and determine the 
downstream differentiation events taking place in interacting cells. Aire expres-
sion depends on the interactions between RANKL+ thymocytes and RANK+ 
mTEC (Akiyama et al. 2008, Hikosaka et al. 2008, Irla et al. 2008). Aire protein 
in antigen-presenting mTEChi, on the other hand serves as a crucial factor 
regulating the expression of thousands of TSA required in thymocyte negative 
selection (Anderson et al. 2002, Sansom et al. 2014). Although recent publi-
cations have broadened our understanding on how Aire induces PGE in thymus 
[reviewed in (Anderson & Su 2016, Abramson & Anderson 2017), the tran-
scriptional mechanisms underlying the specific activation of Aire itself in 
mTEChi in response to RANK-signaling are currently unknown. The authors 
who identified the murine homologue of the human AIRE gene, also found a 
highly conserved region upstream of the AIRE gene and theorized that it may 
have a role in modulating AIRE expression (Blechschmidt et al. 1999). But until 
present day this hypothesis has not been validated.  
During pregnancy the thymic volume and thymocyte output are drastically 
decreased in mammals (Chambers & Clarke 1979, Shinomiya et al. 1991, 
Clarke & Kendall 1994, Tibbetts et al. 1999). In pregnant mice this process 
appears to be required for the normal fetal development and has been speculated 
to benefit to the maternal-fetal tolerance (Tibbetts et al. 1999). The effects of 
pregnancy on thymocytes have been described (Tibbetts et al. 1999, Zoller et al. 
2007), but whether pregnancy also affects the thymic stromal compartment, 
responsible for the induction of central tolerance is unknown. It is also unknown 
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whether the hormonal changes during pregnancy have a direct effect on 
thymocytes or is thymic involution, at least in part, mediated by transcriptional 
events called forth in thymic stromal cells. 
Irf4 is a transcriptional regulator initially thought to be expressed exclusively 
in lymphocytes (Pongubala et al. 1992, Matsuyama et al. 1995, Grossman et al. 
1996, Yamagata et al. 1996). However, it has been found to be expressed in 
multiple cell-types in- and outside of the immune system (Eguchi et al. 2011, 
Nakashima & Haneji 2013, Praetorius et al. 2013, Guo et al. 2014, Nam & Lim 
2016) Regardless of the lineage of the specific Irf4-expressing cell-type, Irf4 
appears to act as a key regulator of development and/or function in these cells. 
As several peripheral APC rely on Irf4 in their function (Nam & Lim 2016), we 
asked, whether this protein might also have a role in the differentiation or 
function of TEC which represent a rare population of APC of the epithelial 
lineage. 
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3. AIMS OF THE STUDY 
 
1. To characterize the in vivo role of a highly conserved noncoding sequence 
upstream of the Aire coding region. 
2. To describe the changes in the stromal compartment during PRTI and to 
determine the specific transcriptional changes in thymic stroma contributing 
to PRTI during normal murine pregnancy. 
3. To determine the in vivo role of Irf4, a master regulator of peripheral 
immune cell differentiation and function, in thymic epithelial cells. 
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4. MATERIALS AND METHODS 
 
4.1.  Mice 
 
All mice were maintained at the Vivarium of the Institute of Biomedicine and 
Translational Medicine, University of Tartu. CNS1-KO mice were generated at 
the Laboratory Animal Centre of Tartu University by targeted disruption of the 
CNS1 region. The vector was electroporated into 129S6/SvEvTac (W4) ES 
cells followed by G418 selection and in vitro Cre-recombination. Achieved 
clones were injected into C57BL/6J embryos and obtained chimeras were 
crossed with C57BL/6 mice. The mice were maintained on mixed 129sv/ 
C57BL/6 background and crossed as heterozygous CNS1+/− mice. C57BL/6 
mice deficient for the Aire gene were generated at the Walter and Eliza Hall 
Institute for Medical Research by a targeted disruption of Aire gene in exon 8. 
The mice were maintained and crossed as Aire+/− mice. TEC-specific condi-
tional Irf4-deficient mouse strain was generated by crossing mice with the Irf4 
gene flanked by loxP sites (Irf4fl/fl) (B6.129S1-Irf4tm1Rdf/J, The Jackson 
laboratory) (named WT here) and FoxN1:Cre mice (a kind gift from Thomas 
Boehm). F1 mice heterozygous for FoxN1:Cre and Irf4fl/fl were crossed with 
Irf4fl/fl resulting in mice lacking the first two exons of Irf4 and expressing GFP 
in FoxN1:Cre expressing tissues. In experiments concerning knockout mice 
male and female mice were used in equal proportions. In Study I 4-6-week-old 
Aire-KO/CNS1-KO and WT littermate controls were used. In Study III 8-10-
week-old Irf4-cKO mice and WT controls were used for all studies except 
determining of mononuclear infiltrations from aged mice. In Study II, 
pregnancy was determined by the presence of a vaginal plug and thymi were 
collected at three time points during the pregnancy: during the first (3–5 days), 
second (10–12 days), and third (17–19 days) trimesters. Age-matched virgin 
female mice were used as controls. All animal experiments were approved by 
the ethical committee of animal experiments at the Ministry of Agriculture, 
Estonia. 
 
 
4.2.  Flow cytometry and FACS 
 
The antibodies used in the studies are listed in the Table 1. For purification, 
thymi were minced and gravity-sedimented several times in RPMI-1640 media 
containing 2% FBS and 20 mM HEPES. The enriched stromal compartment 
from each genotype was pooled and enzymatically digested in RPMI-1640 
media containing collagenase 2 (125 U/mL; Gibco) and DNase1 (15 U/mL; 
AppliChem) for 20 min at room temperature followed by two 20-minute diges-
tions with collagenase 2, DNase1 and Dispase (0.75 U/mL; Gibco). Following 
FcR blocking in 2.4G2 hybridoma medium, thymocytes and stromal cells were 
counted and stained for FACS-sorting or analysis. For thymocyte and lympho-
cyte analysis thymi and spleens were homogenized using glass-slides, erythro-
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cytes in the spleens were lysed using osmotic shock: cells were resuspended in 
900 μL deionized water and 100 μL 10 × PBS was added after 10 s. Cells were 
strained, counted, incubated in 2.4G2 FcR-blocking medium and stained with 
respective antibodies. All experiments were analyzed using LSRFortessa flow-
cytometer with FACSDiva software (BD Biosciences) or FCS Express 5 Flow 
(De Novo Software) 
 
 
Table 1. Antibodies used in flow cytometry and FACS 
 
Fluorescence-activated cell sorting and 
flow cytometry antigens and antibody 
clones Conjugate Company 
Aire (5H12) eFluor660 eBioscience 
B220 (MCA1258F) FITC Serotec 
CD11c (N418) BV421 Biolegend 
CD25 (PC61.5) APC eBioscience 
CD3 (145.2C11) PerCP-Cy5.5 eBioscience 
CD4 (GK1.5) APC-eFluor 780 eBioscience 
CD4 (RM4-5) APC BD Biosciences 
CD44 (IM7) PerCP-Cy5.5, PE eBioscience 
CD45 (30-F11) PerCP-Cy5.5 eBioscience 
CD62l (MEL-14)  Pe-Cy7 eBioscience 
CD8 (53-6.7) eFluor 650NC eBioscience 
EpCAM (G8.8) Pe-Cy7 eBioscience 
ERTR7 (ab51824)*   Abcam 
FoxP3 (FJK-16s) FITC eBioscience 
Helios (22F6) APC eBioscience 
I-A/I-E (M5/114.15.2) APC eBioscience 
I-A/I-E (M5/114.15.2) BV510 Biolegend 
Irf4 (3E4) BV450 eBioscience 
Ki67 (B56) PE BD Biosciences 
Ly51 (BP1) PE eBioscience 
Nrp1 (3E12) BV421 Biolegend 
UEA-1-lectin  FITC Vector labs 
   
* Conjugated in-house with Alexa Fluor 647 Monoclonal Andibody Labeling Kit 
(Invitrogen). 
 
 
4.3.  RNA Purification and RT-PCR 
 
RNA purification was carried out by either TRIzol–chloroform extraction 
(whole tissues) or with RNeasy Micro Kits (Qiagen; sorted cells and 
FTOCs) according to manufacturers' protocols, followed by reverse tran-
scription using SuperScript III Reverse Transcriptase (Life Technologies). 
Primers used in the study are listed in Table 2. All RT-PCRs were carried out 
on ViiA™ 7 real-time PCR system. Every sample was run in three parallel 
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reactions. Relative gene expression levels were calculated using the compara-
tive Ct (ΔΔCt) method (according to Applied Biosystems), where the relative 
expression is calculated as 2−ΔΔCt, and where Ct represents the threshold cycle. 
β2-microglobulin and cytokeratin 8 were used as house-keeping genes for 
normalization.  
 
 
 
Table 2. Primer sequences used for gene expression analysis in RT-PCR 
 
Oligo name Sequence 5’ → 3’ Gene  
CCL17 F AGTGGAGTGTTCCAGGGATG Ccl17 
CCL17 R CCAATCTGATGGCCTTCTTC Ccl17 
CCL19atg F CTGCCTCAGATTATCTGCCAT Ccl19 
CCL19atg Rnew CTTCCGCATCATTAGCACCC Ccl19 
CCL20 F CAGAAGCAAGCAACTACGAC Ccl20 
CCL20 R TCTTCGTGTGAAAGATGATAGC Ccl20 
CCL21 F CCCTGGACCCAAGGCAGT Ccl21 
CCL21 R AGGCTTAGAGTGCTTCCGGG Ccl21 
CCL22 F CATTCTTGCTTCCCTGGAGA Ccl22 
CCL22 R TCAGAGAGGAAAAGCGATCC Ccl22 
CCL25 F GTGCTGTGAGATTCTACTTCC Ccl25 
CCL25 R TATGGTTTGACTTCTTCCTTTCAG Ccl25 
CCL5 F GTGCCCACGTCAAGGAGTAT Ccl5 
CCL5 R CCCACTTCTTCTCTGGGTTG Ccl5 
CD40 F GCTATGGGGCTGCTTGTTGA Cd40 
CD40 R ATGGGTGGCATTGGGTCTTC Cd40 
CD86 F TGAGTATGGTGATAACATGCAG Cd86 
CD86 R ACTCTTGAGTGAAATTGAGAGG Cd86 
Crp F CCTTCTGATCATGATCAGCT Crp 
Crp R CATAAGAGAAGACACTGAAGCTG Crp 
CSNb F GGCACAGGTTGTTCAGGCTT Csn2 
CSNb R AAGGAAGGGTGCTACTTGCTG Csn2 
CXCL12 F CATCAGTGACGGTAAACCAG Cxcl12 
CXCL12 R CACAGTTTGGAGTGTTGAGG Cxcl12 
DLL4 F AGGTGCCACTTCGGTTACAC Dll4  
DLL4 R GGGAGAGCAAATGGCTGATA Dll4 
Dnmt3l CGGTGGAACTGGAACAT Dnmt3l 
Dnmt3l F1 AACGCTGAAGTACGTGGA Dnmt3l 
Dsg1 f CTTAGGATTGGTTCCATTCCTG Dsg1 
Dsg1 R CCATTAGTTCAAATCCTGTGGT Dsg1 
DSG3 F TTCGGAAGGTACAATTCATCAG Dsg3 
DSG3 R TGCAAACTTCAGAGCTTTCC Dsg3 
GAD1 F ATAGAAAGGGCCAATTCAGTC Gad1 
GAD1 R TGCATCCTTGGAGTATACCC Gad1 
IL1B F1 CAACCAACAAGTGATATTCTCCATG Il1b 
IL1B R1 GATCCACACTCTCCAGCTGCA Il1b 
IL6 F TTAAGGAGCTTATTGAGGAGCTG Il6 
IL6 R CTACACAGAACCCGCCA Il6 
IL7 F TGATGATACAAAGGAAGCTGC Il7 
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Oligo name Sequence 5’ → 3’ Gene  
IL7 R GCCTTGTGATACTGTTAGTAAGTG Il7 
Irf4 ex2 F TCTTCAAGGCTTGGGCATTG Irf4  
Irf4 ex2 R CACATCGTAATCTTGTCTTCCAAGTAG Irf4  
Kit L F TCAACATTAGGTCCCGAGAAA Kit l  
Kit L R ACTGCTACTGCTGTCATTCCTAAG Kit l 
KRT10 R GTAGTTCAATCTCCAGACCC Krt10  
KTR10 F GTTCAATCAGAAGAGCAAGGA Krt10 
KRT2-8 F AGGAGCTCATTCCGTAGCTG Krt8 
KRT2-8 R TCTGGGATGCAGAACATGAG Krt8 
KRT6b F CAAACTCACATCTCAGACAC Krt6b 
KRT6b R GCAGCTCCTCATATTTAGTC Krt6b 
QmAIRE3/4 5f CCTCAAAGAGCGTCTCCAG Aire 
QmAIRE3/4 5r TGGTCTGAATTCCGTTTCCA Aire 
mAire_ex7/9 F GTTAACCAGAAGAACGAGGATGAG Aire 
mAire_ex7/9 R AGCAGGAGCATCTCCAGAG Aire 
mB2mF TGAGACTGATACATACGCCTGCA β2m 
mB2mR GATGCTTGATCACATGTCTCGATC β2m 
mCD80 F GTCCATCAAAGCTGACTTCTC Cd80 
mCD80 R ATGCCAGGTAATTCTCTTCCA Cd80 
mE2F3_f CAAGGTGCAGAAGAGGAGGA E2f3 
mE2F3_r GAGGTCCAGGGTACAGCTTT E2f3 
mH2-Aa F CTCAGAAATAGCAAGTCAGTC H2-Aa 
mH2-Aa R AATCTCAGGTTCCCAGTG H2-Aa 
mIns2 F1 GCTTCTTCTACACACCCATGTC Ins2 
mIns2 R1 AGCACTGATCTACAATGCCAC Ins2 
mINV F GTGAGTTTGTTTGGTCTACAG Ivl 
mINV R GAAAGCCCTTCTCTTGAATCTC Ivl 
mTff3_exp_F TGTTGGCTGTGAGGTCTTTA Tff3 
mTff3_exp_sh2_R CTGTGCAGTGGTCCTGAA Tff3 
Mup3 F GCAGCAGCAGCTTCATTTT Mup3 
Mup3 R AGGTAACATGCTGGAGAGAA Mup3 
mXcl1 F TCTTGATCGCTGCTTTCACC Xcl1 
mXcl1 R GAAGTCCTAGAAGAGAGTAGC Xcl1 
S100A8 F TTTGTCAGCTCCGTCTTCAA S100a8 
S100A8 R AGACAGTCACATAGCCCTAC S100a8 
Saa1 F AGGAGACACCAGGATGAAGC Saa1 
Saa1 R CCAGTTAGCTTCCTTCATGTCAG Saa1 
Spt1_F AACTTCTGGAACTGCTGATTCTG Spt1 
Spt1_R GAGGCCTCATTAGCAGTGTTG Spt1 
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4.4.  Immunofluorescence 
 
Immunofluorescence was performed on frozen sections fixed with acetone or 
4% formaldehyde. Formaldehyde-fixed tissues were permeabilized with 0.1% 
Triton X-100 in PBS. A 30 min blocking step at RT with 1% normal goat serum 
was used. Sections were incubated overnight with indicated primary Ab at 4°C 
(listed in Table 3), washed in PBS, and incubated with a respective secondary 
Ab (1:1000) for 60 min at room temperature. Slides were washed four times 
with PBS, nuclei stained with DAPI (1μg/mL) for 10 min, washed once more in 
PBS, and covered with fluorescent mounting medium (Dako) and coverslips. 
Images were obtained with LSM710 microscope (Zeiss). 
 
 
Table 3. Antibodies used in immunofluorescence experiments 
 
Antigens targeted and antibody clones  Company 
Aire (M-300) Santa Cruz 
Ivl (ab28057) Abcam 
K14 (10143-1-AP) Proteintech 
K8 (Troma-1) (provided by J. Dooley) 
UEA-1-lectin conjugated with FITC Vector Labs 
Irf4 (3E4) conjugated with Brilliant Violet 450 eBioscience 
Alexa Fluor 488 Goat anti rat IgG Invitrogen 
Alexa Fluor 594 Goat anti rabbit IgG Invitrogen 
 
 
4.5.  Mononuclear infiltrations 
 
Livers, pancreases and salivary glands from young (8-10) or aged WT and Irf4-
cKO mice (40-48w) were isolated and fixed in 4% paraformaldehyde in PBS, 
embedded in paraffin, cut into 5-μm sections, and stained with hematoxylin and 
eosin. Images were obtained with Eclipse Ci microscope (Nikon). 
 
 
4.6. Statistics 
 
Statistical significance for flow cytometry and RT-PCR analysis was 
determined by a two-tailed unpaired t-test and for infiltrates by two-tailed 
Mann-Whitney U-test using Prism GraphPad Software (La Jolla, CA).  
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5. RESULTS 
 
5.1.  Study I 
 
5.1.1. CNS1 is indispensable for the thymic expression  
of Aire and Dnmt3l 
 
A highly conserved region of 90 nucleotides speculated to regulate Aire 
expression lies halfway between the Aire and the Dnmt3l genes on chromosome 
10 in the mouse genome (Blechschmidt et al. 1999). This CNS (named CNS1 
here) contains two well-conserved 10 bp motifs (Figure 5) separated by 7-9 
nucleotides in most mammals analyzed (41/48). JASPAR database analysis of 
transcription factor binding sites identified three NF-κB factors (c-rel, Rela and 
p50) to be the most likely candidates to bind the CNS1 in the distal promoters 
of both Aire and Dnmt3l (Study I).   
To determine whether this region has an in vivo function in regulating Aire 
expression, we generated mice with a deletion of 45 bp containing both con-
served sites (Figure 5) and studied Aire expression in the thymus and peripheral 
tissues that have been shown to contain Aire-expressing cells (Gardner et al. 
2008, Schaller et al. 2008, Yamano et al. 2015). The expression of Aire was 
abolished in the thymi, spleens and lymph nodes of CNS1-KO (Figure 6A), but 
unlike in Aire-KO (Figure 6B), was not affected in the testis. We saw a similar 
pattern in the expression of Dnmt3l (Figure 6C), which is a tissue-specific 
methyltransferase expressed mainly in gonocytes (Webster et al. 2005) but has 
also been detected in thymus (Aapola et al. 2000).  
We next verified the decreased Aire expression in sorted TEC-subsets. Aire 
mRNA was highly expressed in the mTEChi population from WT mice, but was 
barely detectable in the mTEChi from CNS1-KO mice (Figure 6D). The low-
level Aire mRNA expression identified in WT mTEClo most likely derives from 
the carryover of mTEChi fraction during cell purification or by the residual 
expression of Aire in the mTEClo subset. We also performed flow cytometry 
analysis to verify whether the absence of Aire mRNA in CNS1-KO was also 
mirrored on protein level. Analysis of Aire expression in UEA+ mTEC revealed 
the mTEChi from CNS1-KO also lacked the expression of Aire protein (Figure 
6E). Collectively, these results demonstrate that Aire expression in lymphoid 
tissues critically depends on CNS1. 
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Figure 6. The deletion of CNS1 region blocks Aire expression in the mouse immune 
cells. The relative Aire mRNA expression from whole tissues of WT and CNS1-KO (A) 
and Aire-KO mice (B) normalized to WT mTEChi expression. (C) The relative Dnmt3l 
mRNA expression from whole tissues of WT and CNS1-KO mice. Data (A-C) are 
shown as the means + SEM from six (spleens, lymph nodes) or three mice (thymi, 
testes) per genotype from a single experiment. (D) Relative Aire mRNA expression in 
sorted thymic stromal cells from WT and CNS1-KO mice was determined by RT-PCR; 
nd, not detected. (E) Percentage of Aire-expressing cells in WT and CNS1-KO UEA+ 
populations from six pooled thymi was determined by flow cytometry. **p ≤ 0.05, **p 
≤ 0.01, ***p ≤ 0.001, unpaired t-test, two-tailed. 
 
 
 
 
5.1.2. Deletion of the Aire CNS1 results in  
an Aire-KO thymic phenotype 
 
In mTEChi thousands of genes are induced by Aire (Sansom et al. 2014). 
Multiple genes involved in mTEC differentiation (Yano et al. 2008, Wang et al. 
2012) and thymocyte migration (Laan et al. 2009, Lei et al. 2011) are expressed 
in an Aire-dependent manner, but most notably Aire is known to regulate the 
expression of TSA (Anderson et al. 2002, Sansom et al. 2014). To determine 
whether the lack of Aire expression in the thymi of CNS1-KO results in a 
similar phenotype as Aire-KO, we analyzed the mTEC subtypes by flow 
cytometry and studied the expression of Aire target genes in sorted mTEChi by 
RT-PCR. Our flow cytometry analysis of UEA+ cells revealed the mTEChi 
population to be increased in CNS1-KO (Figure 7A). This is similar to our 
results from Aire-KO (Figure 7B) and those reported earlier (Anderson et al. 
2002, Gray et al. 2007a). 
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Figure 7. CNS1-KO and Aire-KO mice have similar thymic phenotypes. The per-
centages of mTEC subpopulations in WT and CNS1-KO (A) and Aire-KO mice (B) 
were evaluated by flow cytometry. Plots shown are representative of three independent 
experiments with pooled thymi (4-6 mice per genotype). Relative expression of Aire-
dependent maturation markers in CNS1-KO (C) and Aire-KO mice (D) sorted mTEChi 
population was measured by RT-PCR. The relative expression of Aire-dependent 
chemokines in sorted mTEChi populations from CNS1-KO (E) and Aire-KO mice (F) 
was determined by RT-PCR.  
 
 
mTEChi are thought to differentiate past the Aire-positive stage (Nishikawa et 
al. 2010) with Aire expression being a pre-requisite for the terminal diffe-
rentiation of mTEChi (Yano et al. 2008, Laan et al. 2009). Similarly to Aire-KO 
the expression of mTEChi terminal differentiation markers Krt6, Krt10, Ivl and 
Dsg3 were decreased in the sorted mTEChi of CNS1-KO mice whereas the 
expression of H2-Aa (a MHCII gene) and CD80 were increased (Figure 7C and 
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Figure 7D). The decreased expression of Ccl5, Ccl17, Ccl22 (Ccr4 ligands); 
Ccl19, Ccl21 (Ccr7 ligands); and Xcl1 in CNS1-KO also phenocopies the 
mTEChi from Aire-KO along with increased Ccl25 expression (Figure 7E and 
Figure 7F). Transcript analysis of mTEChi from CNS1-KO and Aire-KO show 
the expression of Aire-dependent TSA such as Tff3, Spt1, Ins2, Saa1 to be 
substantially downregulated with negligible changes in the expression of Csn2, 
an Aire-independent TSA (Study I, Figure 3A and SI Figure 3A). 
 
 
Figure 8. The percentages of Tregs in the thymi of WT and CNS1-KO (A) and Aire-
KO mice (B) were determined by flow cytometry. Data are shown as the means + SEM 
of six mice per group from a single experiment. **p ≤ 0.01, unpaired t-test, two-tailed. 
 
 
Aire-dependent PGE is crucial in central tolerance homeostasis (Anderson et al. 
2002). In addition to mediating thymocyte negative selection, presenting 
peptides from the induced TSA is required to drive the thymic differentiation of 
Tregs (Malchow et al. 2013, Yang et al. 2015b, Malchow et al. 2016). 
Consistent with previous findings (Malchow et al. 2013), the thymi of both 
CNS1-KO and Aire-KO harbored fewer Foxp3+ cells among the CD4+ T cell 
population (Figure 8A and Figure 8B). Surprisingly, when studying peripheral 
Treg populations, we found the Treg in the spleen to be more plentiful among 
CD4+ T cells in CNS1-KO and Aire-KO (Study I, Figure 3I and SI Figure 3H). 
Thus, we conclude that the deletion of the newly described NF-κB-responsive 
enhancer element is sufficient to result in a thymic phenotype indistinguishable 
from Aire-KO. 
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5.2.  Study II 
 
5.2.1. Pregnancy results in a progressive loss of thymocytes and  
thymic nonlymphoid cells 
 
During pregnancy the thymus decreases drastically mainly due to the reduction 
in thymocyte numbers (Clarke & Kendall 1994, Tibbetts et al. 1999, Zoller et 
al. 2007). We first verified the inverse correlation between body mass and 
thymic involution during pregnancy by weighing the mice and their thymi at 
each trimester. When compared to non-pregnant controls thymic involution be-
comes apparent during the second trimester (Study II, Figure 1A), peaking 
during the third trimester accompanied by drastic decreases in both the CD45+ 
and CD45- populations (Figure 9A).  
The decrease in thymic volume is ascribed to the universal drop in the total 
numbers of all major thymocyte populations accompanied by a development 
block at the DN1-DN2 thymocyte stage (Tibbetts et al. 1999, Zoller et al. 2007). 
We found no major changes in the distribution of the classic thymocyte 
populations (DN, DP, SP) during pregnancy, but the total numbers of these 
populations showed a progressive decrease when compared to non-pregnant 
controls. Our data showing the proportional increase of DN1 thymocytes within 
DN cells is in compliance with the previously reported developmental block of 
DN1-DN2 thymocytes during pregnancy (Tibbetts et al. 1999). However, the 
decreased total numbers of DN1 thymocytes indicate a reduction in TLP 
seeding (Study II, Figure 2A, and 2B).  
One of the major mechanisms behind pregnancy induced immune tolerance 
is the accumulation of Tregs to the maternal-fetal interface (Aluvihare et al. 
2004, Ruocco et al. 2014). The main Treg population responsible for inducing 
tolerance towards the semi-allogenic fetus is pTreg (Samstein et al. 2012). As a 
whole, the peripheral Treg population expands during pregnancy (Aluvihare et 
al. 2004), but whether this increase can only be attributed to the induction of 
pTreg is unknown. Therefore we evaluated the proportions and total numbers of 
Tregs in the thymus. Among thymic CD4+ T cells, the proportion of Foxp3+ T 
cells showed a slight but statistically significant increase by the third trimester 
in comparison with non-pregnant controls (Figure 9B and Study II, Figure 2C). 
By the third trimester, however, the total number of Treg had significantly 
declined (Figure 9C) in comparison with non-pregnant controls (Student's t-test: 
p < 0.05, n = 6). 
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Figure 9. The effect of pregnancy on relative and total numbers of lymphoid and 
stromal cells. (A–D) C57BL/6 nonpregnant control mice (c) and mice during the first 
(Tri1), second (Tri2), and third (Tri3) trimesters of pregnancy were studied (A) Total 
numbers of thymic CD45+ and CD45− cells were analyzed by flow cytometry 
(Spearman rank correlation between CD45+ and the length of pregnancy: p < 0.05, r = 
−0.6, and between CD45− and the length of pregnancy: p < 0.05, r = −0.8). Relative 
numbers (B) and total numbers (C) of thymic Foxp3+ Treg cells are shown (Spearman 
rank correlation between the length of pregnancy and the total number of Treg cells: p < 
0.05, r = −0.9). Data (A, B, C) are shown as mean + SEM (n = 3 mice/group) and are 
from a single experiment. (D) Relative numbers of the indicated stromal cell 
populations were measured by flow cytometry (Spearman rank correlation between the 
length of pregnancy and the total numbers of all stromal cell populations measured: p ≤ 
0.05, r ≥ −0.6. *Student's t-test, p < 0.05). Data are shown as mean + SEM (n =  
3 mice/group) and are from a single experiment. 
 
 
As with thymocytes, the effect of normal pregnancy on the thymic non-
lymphoid cells becomes apparent during the second trimester of pregnancy. The 
total numbers of all the five major stromal cell populations analyzed (mTEChi, 
mTEClo, cTEC, fibroblasts and DC) showed a progressive decrease during 
pregnancy (Study II, Figure 3A). However, substantial differences arise in the 
cellular composition of thymic non-lymphoid cells between the non-pregnant 
controls and mice during the third trimester of pregnancy. There were no 
changes in the proportions of DC among CD45+ cells. mTEChi decreases 
drastically in numbers and also in proportion among CD45- cells. The pro-
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portion of mTEClo remained unchanged whereas the proportions of cTEC and 
fibroblast were significantly increased by the third trimester (Figure 9D). 
  
 
5.2.2. Pregnancy hinders TEC proliferation and TLP seeding 
 
In ARTI the loss of thymic tissue is associated with a downregulation of the 
activity of a transcription factor E2f3 in mTEClo and cTEC resulting in 
nonproliferating TEC-populations (Ki et al. 2014). Similarly we found E2f3 
mRNA to be critically downregulated in the same highly proliferative cell popu-
lations in PRTI (Figure 10A). Contrary to ARTI (Ki et al. 2014) we witnessed a 
slight decrease in the expression of inflammatory cytokines IL1b and IL6 in DC 
and fibroblasts, respectively. In addition to the decreased expression of Dll4 
reported in ARTI (Ki et al. 2014), we found the expression level of Kitl and IL7 
also to be downregulated in late pregnancy, suggesting a potential role for the 
stromal cell-provided microenvironment in the pregnancy-induced block in 
thymocyte development and proliferation.  
 
 
Figure 10. The effect of pregnancy on thymic nonlymphoid cells and dendritic cells 
(DCs). Gene expression profiles in different stromal cell populations in control mice (C) 
and in pregnant mice during the third trimester (Tri3). Data are shown as means + SEM 
of three technical replicates of one experiment performed in a pooled sample from four 
to six mice per group. 
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5.2.3. Pregnancy induces a decrease in the expression of ligands for 
Ccr9, Cxcr4, and Ccr7 
 
In order to delineate the contribution each stromal subset has in producing chemo-
kines required for TLP homing, we analyzed the expression of ligands for Ccr7 
(Ccl19 and Ccl21), Ccr9 (Ccl25) and Cxcr4 (Cxcl12) in the purified thymic 
stromal sets. Each chemokine measured had its distinct cellular source: Ccl25 
was predominantly produced by cTEC, Cxcl12 by fibroblasts and cTEC, Ccl21 
by mTEClo, and Ccl19 by mTEChi (Figure 11). In the same populations isolated 
from pregnant mice we observed a decrease in the production of all chemokines 
by their respective predominant cellular source by late pregnancy (Figure 11). 
Previous reports have indicated either estrogen or progesterone in pregnancy-
induced thymic involution (Tibbetts et al. 1999, Zoller et al. 2007). To deter-
mine whether either of the hormones mediates the changes in thymic stromal 
chemokine expression pattern, we analyzed purified thymic stromal cells from 
non-pregnant mice treated with either estrogen or progesterone. Contrary to 
estrogen treatment, short-term treatment with progesterone resulted in a signi-
ficant decrease in Ccl25 and Cxcl12 expression in cTEC and Ccl21 expression 
in mTEClo (Study II, Figure 5) suggesting that the pregnancy-induced sup-
pression in chemokine expression is at least partly mediated by progesterone. 
 
Figure 11. The effect of pregnancy on chemokine expression in thymic stromal cells. 
The expression levels of chemokines were measured by RT-PCR in different thymic 
stromal populations purified from the thymi of non-pregnant C57BL/6 control mice (C) 
and from pregnant mice during the first (1), second (2), and third (3) trimesters. Data are 
shown as mean + SEM of three technical replicates of one experiment performed in a 
pooled sample from four to six mice per group. 
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Collectively, these data indicate that in thymic stromal subsets the events during 
pregnancy result in a widespread downregulation in the expression of multiple 
proteins required for the homing and progenitor niche of the TLP. 
 
 
5.3. Study III 
 
5.3.1. RANK signaling induces Irf4 in the thymic epithelium 
 
As the differentiation and antigen presenting capacity of peripheral APC such as 
DC, B cells and Mϕ is impaired in Irf4-deficiency (Nam & Lim 2016), we 
aimed to characterize the role of Irf4 in TEC that represent epithelial APC with 
pivotal role in central tolerance induction. Our RT-PCR analysis from sorted 
WT TEC revealed that all the major TEC-subsets express Irf4 mRNA with 
highest levels in mTEChi (Figure 12A). The differential expression of Irf4 
mRNA was also mirrored on the protein level with roughly two-thirds of the 
mTEChi and up to a third of both mTEClo and cTEC being positive for Irf4 
expression (Figure 12B). 
 
 
Figure 12. Thymic epithelium constitutively expresses Irf4. (A) Relative Irf4 mRNA 
expression level in WT TEC subsets. (B) Irf4 protein expression in WT TEC subsets. 
Data are representative of two experiments from pooled WT thymi from four mice and 
are shown as means + SEM.  
 
 
Developing thymocytes produce several proteins shown to regulate the 
maturation and gene expression profile of the thymic epithelial compartment 
(Akiyama et al. 2012). To identify the specific ligands for TNFSF receptors that 
drive Irf4 expression in the thymic epithelium we used fetal thymic organ 
cultures (FTOCs), which we stimulated with several ligands known to have a 
functional role in TEC maturation. Among the TNFSF-members analyzed 
(RANKL, CD40L, Light, TNFα, LTβR agonist), we found RANKL to be the 
only TNFSF-member to induce Irf4 mRNA in thymocyte-depleted FTOC 
(Study III, Figure 1C). The costimulation of FTOC with RANKL alongside 
with CD40 or LTβR has been shown to have a synergistic effect on the 
expression of Aire and Fezf2 genes in TEC (Bichele et al. 2016); however Irf4 
expression was not increased in FTOC following either of the costimulations 
(Study III, Figure 1C). 
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As RANK-signaling can activate both the classical and non-classical NF-κB 
pathway, we wanted to determine the predominant pathway in thymic 
epithelium-specific Irf4 expression. Therefore we treated RANK-induced 
FTOCs either with TPCA-1, a classical NF-κB pathway inhibitor with high 
selectivity for IKK-β over IKK-α or a selective NIK inhibitor (isoquinoline-
1,3(2H, 4H)-dione), which blocks the alternative NF-κB pathway. Even low 
concentrations of the IKK-β inhibitor had a substantial effect on Irf4 expression 
(Study III, Figure 1D), whereas using the NIK inhibitor resulted in a non-
significant but strongly trending decrease in Irf4 expression. 
Based on these results we conclude that the so far undescribed Irf4 expression 
in TECs is constitutive and components from the classical NF-κB pathway are 
critical for the activation of Irf4 downstream of RANK-RANKL binding. 
 
 
5.3.2. Irf4 regulates the maturation of thymic epithelium 
 
To establish the role of Irf4 in thymic epithelium we next generated TEC-
specific Irf4-deficient mice by crossing Irf4fl/fl mice (Klein et al. 2006) (referred 
from hereon as WT) with FoxN1:Cre mice (kind gift from T. Boehm). 
According to Mendelian distribution, a proportion of the F2 progeny of these 
mice are deficient in Irf4 expression in FoxN1:Cre expressing cells (referred to 
here as Irf4-cKO) and express GFP in tissues co-expressing FoxN1:Cre and 
Irf4. We verified the induction of GFP expression in TEC subtypes by flow-
cytometry and found the levels of TEC subtypes in Irf4-cKO expressing GFP 
(Figure 13A) and Irf4-expressing TEC in the WT mice (Figure 12B) to be 
comparable. 
According to our immunofluorescence analysis (Figure 13B), in WT mice 
Irf4 is predominantly expressed in the thymic medullary compartment by 
Krt14+ cells. In Irf4-cKO, however, Irf4 is expressed on a substantially lower 
level and its expression is mainly restricted to Krt14- cells that could possibly 
represent CD69hi T cells or thymic DC (Cao et al. 2010, Yamamoto et al. 2011, 
Nayar et al. 2012). We carried out a flow cytometric analysis of the thymic 
stromal compartment of WT and Irf4-cKO to find the only differences in the 
stromal compartment to be the significantly decreased mTEClo/mTEChi ratio in 
the Irf4-cKO mice (Figure 13C and Study III, SI Figure 1D). Our immuno-
fluorescence analysis for mTEC marker Krt14, mature mTEC marker UEA-1, 
or terminally differentiated TEC positive for Ivl revealed no robust differences 
between the genotypes (Study III, Figure 2C). Therefore, based on our flow 
cytometry results we conclude that Irf4 regulates the differentiation from the 
mTEClo subpopulation to mTEChi. 
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Figure 13. Irf4 regulates mTEC maturation. (A) GFP-protein expression in Irf4-cKO 
TEC subsets occurring after the excision of the first two exons of Irf4. (B) Thymic 
sections from WT and Irf4-cKO mice were stained for Irf4 (blue) and Keratin 14 (red). 
Images shown are representative of three mice per genotype from two independent 
experiments. Scale bar is 100 µm. (C) The percentages of mTEC subpopulations in WT 
and Irf4-cKO mice were evaluated by flow cytometry. Plots shown for (A) and (C) are 
representative of four independent experiments. Data for (A) and (C) are shown as the 
means + SEM from four independent experiments with pooled thymi (n = 3–6). ***p ≤ 
0.001, unpaired t test, two-tailed. 
 
 
5.3.3. Irf4 expression is essential for priming thymic  
epithelium into efficient Treg inducers 
 
To establish whether the altered Irf4-deficient mTEC profile influences thymo-
cyte differentiation, we analyzed thymocyte and peripheral T cell subpopu-
lations by flow cytometry. Our results from 8-10-week-old mice imply that the 
intrathymic differentiation of the major thymocyte populations (DN subpopula-
tions, DP; and CD4+ and CD8+ thymocytes) is unperturbed in Irf4-cKO. Like-
wise, we found no differences in the distribution of mature CD4+ and CD8+ T 
cell populations in the spleens and inguinal lymph nodes of the Irf4-cKO mice 
(Study III, Figure 3A; and data not shown). However, analysis of the thymic 
Foxp3+ expressing Tregs among CD4+ T cells revealed a 50% decrease in this 
population in Irf4-cKO (Figure 14A). This phenotype did not extend to the 
periphery, as we found the percentages of splenic Tregs among CD4+ T cells in 
Irf4-cKO to be restored to WT levels (Study III, Figure 3C). Arguing for a 
homeostatic peripheral compensation is the fact that the total Treg numbers that 
were decreased in the thymi of Irf4-cKO were also restored to WT levels in the 
spleens (Figure 14B). 
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Figure 14. Irf4 primes TEC for Treg induction. Percentages of Foxp3+ Tregs among 
thymic CD4+ T cells (A) were evaluated by flow cytometry. Plots shown are 
representative of three independent experiments (n = 4–6). (B) Absolute numbers of 
Foxp3+ Tregs from the thymi and spleens of WT and Irf4-cKO mice from two 
independent experiments (n = 4). (C) Distribution of activated and resting Tregs in the 
spleens of WT and Irf4-cKO mice. Plots shown are representative of two independent 
experiments (n = 4–6). Data (A–C) are shown as the means + SEM. *p ≤ 0.05, ***p ≤ 
0.001, unpaired t test, two-tailed. 
 
 
We hypothesized that the decrease in Tregs observed in the thymus could be the 
result of decreased proliferation; therefore we analyzed Ki-67 expression in 
Tregs. Contrary to our expectations, Tregs in both the thymus and spleens of 
Irf4-cKO expressed higher levels of the proliferation marker Ki-67 (Study III, 
Figure 3E). To differentiate between the resting and activated Treg phenotypes, 
we also analyzed the expression of CD44 and CD62L on the splenic Tregs from 
WT and Irf4-cKO. We found no differences in the activated CD44+CD62L- 
Tregs. However we witnessed a subtle but significant decrease in the resting 
CD44-CD62L+ splenic Tregs in Irf4-cKO (Figure 14C).  
 
 
5.3.4. Irf4-deficiency results in an increased induction of pTregs and 
peripheral mononuclear infiltrations 
 
tTreg that are induced by central tolerance in the thymus express both Nrp1 and 
Helios in steady state, whereas pTregs, induced by peripheral tolerance 
mechanisms, do not. Using either protein alone as a tTreg marker has been 
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shown to be controversial (Lin et al. 2013, Szurek et al. 2015), therefore we 
defined tTregs as Tregs positive for both these markers as suggested in (Lin et 
al. 2013). To determine the mechanisms leading to the peripheral compensation 
of Tregs, we assessed the prevalence of Helios+Nrp+ tTregs among all Tregs in 
WT and Irf-cKO mice. We found no differences in the proportions of tTregs or 
pTregs among the bulk Treg population (Study III, Figure 4A). However, 
whereas among thymic CD4+ T cells both pTregs and tTregs had decreased, 
only the proportion of pTregs (Figure 15A) showed a significant increase 
among the splenic CD4+ T cells. More specifically, we found this increase to be 
associated with the increase of activated pTregs among Tregs in Irf4-cKO 
(Figure 15B). Furthermore, we found the decrease seen in resting bulk splenic 
Treg population (Figure 14C) to derive from the reduced population of resting 
tTregs in Irf4-cKO (Figure 15B). 
 
 
 
Figure 15. Irf4-cKO mice have increased induction of pTregs and mononuclear in-
filtrations in the salivary gland. (A) Distribution of pTregs and tTregs among thymic 
and splenic CD4+ SP cells was evaluated by flow cytometry. (B) Distribution of 
activated and resting tTregs and pTregs among Tregs in the spleens of WT and Irf4-
cKO mice was evaluated by flow cytometry. Data (A–B) are shown as the means + 
SEM from a single experiment with six mice per genotype. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001, unpaired t test, two-tailed. (C) H&E-stained tissue slides from aged (40–
48 wk.) WT and Irf4-cKO salivary glands. Infiltrations in the salivary glands are 
marked by a Blackstar. Images shown are representative of four mice per genotype from 
two independent experiments. Scale bar 500 μm. (D) Quantitation of salivary gland 
lesions from aged (40–48 w) WT and Irf4-cKO mice. Data are shown for salivary 
glands of individual mice with median (horizontal line). *p ≤ 0.05, Mann–Whit-
ney U test, two-tailed. 
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Although the peripheral Treg pool is compensated for in Irf4-cKO, we found 
aged (40–48 wk.) but not young (8–10 wk.) Irf4-cKO mice to develop mild 
inflammatory lesions in their salivary glands (Figure 15C) but not livers or 
pancreases (Study III, Figure 4D). The incidence of salivary gland inflammatory 
lesions in Irf4-cKO was significantly higher than in age-matched WT animals, 
whose lesions in salivary glands were less frequent (Figure 15D). 
 
 
5.3.5. Irf4 induces Treg differentiation autonomously of Aire by 
altering chemokine and costimulatory molecule expression levels 
 
Multiple aspects of the phenotype witnessed in Irf4-cKO resemble those present 
in Aire-KO, specifically the altered mTEClo/mTEChi ratio (Matsumoto 2011), a 
reduced Treg population in the thymus (Malchow et al. 2013, Yang et al. 
2015b) and inflammatory lesions in the salivary gland (Anderson et al. 2002). 
Aire and Aire-dependent promiscuous gene expression in mTEChi has been 
shown to be involved in Treg differentiation through rescuing autoreactive 
thymocytes from apoptosis and diverting them toward the Treg lineage 
(Malchow et al. 2016). As we found Irf4 to be upregulated in sorted mTEChi 
from Aire-KO mice (Figure 16A), we asked whether the two phenotypes could 
be interconnected with one transcriptional regulator controlling the expression 
of the other. However, our RT-PCR from sorted mTEChi and flow cytometric 
analysis of the mTEChi population from Irf4-cKO failed to reveal differential 
expression of Aire both on mRNA (Figure 16B) and protein level with ∼40% 
mTEChi from both WT and Irf4-cKO expressing comparable levels of Aire 
protein (Study III, Figure 5C). Furthermore, although there were differences in 
the expression of Aire-dependent and independent antigens in mTEChi of Irf4-
cKO, there was no clear up- or downregulation of the groups of genes studied in 
Irf4-cKO (Study III, Figure 5D). Multiple proteins indicated in end-stage mTEC 
differentiation are controlled by Aire (Yano et al. 2008, Wang et al. 2012), 
however our RT-PCR analysis revealed the maturation programs of Irf4-cKO 
and Aire-KO to differ from one another. We found the mTEChi from Irf4-cKO 
to express slightly decreased levels of the MHCII molecule H2-Aa and in-
creased expression of terminal differentiation markers Krt6 and Ivl (Figure 
16C). In Aire-KO on the other hand, mTEC are arrested in the mTEChi stage 
expressing high levels of H2-Aa and express significantly lower levels of Krt6 
and Ivl when compared to WT (Yano et al. 2008, Wang et al. 2012). 
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Figure 16. Irf4 regulates chemokine and costimulatory molecule expression in 
mTEChi independently of Aire. (A) Relative expression of Irf4 mRNA in sorted mTEChi 
from Aire-KO. (B) Relative expression of Aire mRNA in sorted mTEChi from Irf4-
cKO. Data (A and B) are shown as the means + SEM from two independent 
experiments from pooled thymi (n = 3–6). Relative expression of Aire-dependent and -
independent maturation marker (C) and Aire-dependent chemokine (D) mRNA in the 
sorted mTEChi of WT and Irf4-cKO was measured by RT-PCR. Relative expression of 
costimulatory molecules (E) in the sorted mTEChi of WT and Irf4-cKO was measured 
by RT-PCR. Data (C-E) are shown as the means + SEM of three technical replicates 
from a single experiment from pooled sample (n = 8) and are representative of two 
experiments. 
 
 
Our flow cytometric analysis dissecting the different thymocyte maturation 
stages showed the cTEC-dependent thymocyte differentiation steps to be 
unperturbed in Irf4-cKO (Study III, Figure 3A). Hence, we sought to determine 
the mTEC-specific factors regulating the migration and end-stage maturation 
steps of SP thymocytes. The entry of SP thymocytes into thymic medulla 
depends on the mTEC-specific secretion of several chemokines (Laan et al. 
2009) that act as ligands for chemokine receptors expressed on thymocytes. The 
generation of Tregs in the medulla has been shown to depend on interactions 
between costimulatory molecules such as CD40, CD80 and CD86 expressed on 
mTEChi and their respective ligands on thymocyte cell surface (Williams et al. 
2014). Therefore we used RT-PCR to analyze the gene expression levels of 
chemokines indicated in thymocyte entry to the medulla and costimulatory 
molecules required for Treg induction therein. The levels of Ccl5, Ccl17, 
and Ccl22 that direct thymocyte migration into the medulla were drastically 
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decreased in the sorted mTEChi population from Irf4-cKO, with a subtle but 
consistent drop in the levels of Ccl19 and Ccl21 (Figure 16D). The levels of 
Ccl20 remained unaltered, whereas Ccl25 was increased in the sorted mTEChi 
of Irf4-cKO. Our RT-PCR analysis of costimulatory molecule expression on 
mTEChi revealed a decrease in the expression of CD40 and CD80 with smaller 
changes in the expression of CD86 (Figure 16E), which has common receptors 
on Tregs with CD80. 
In conclusion, our analysis suggests that the thymic Treg phenotype wit-
nessed in Irf4-cKO derives from the altered chemokine and costimulatory 
molecule expression pattern in the mTEChi population of Irf4-cKO mice. 
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6. DISCUSSION 
 
6.1.  CNS1 enhancer region regulates Aire expression  
in lymphoid tissues 
 
The Aire protein represents an exceptional transcriptional regulator central in 
immune tolerance induction. It is well-established that Aire-mediated PGE is 
crucial in the generation of an immunocompetent T cell pool (Klein et al. 2014). 
This is best exemplified by the fact that mutations in the Aire gene are sufficient 
to cause grave immunodeficiency in human patients as well as in Aire-KO 
murine models (Consortium 1997, Nagamine et al. 1997, Anderson et al. 2002). 
However our understanding of the tightly controlled transcriptional mechanisms 
leading to Aire expression in mTEChi is only beginning to expand. For instance, 
it is known that in mTEChi, Aire expression is specifically upregulated follo-
wing RANK-stimulation. RANK-signaling results in the non-specific activation 
of the classical and alternative NF-κB pathways, both of which have been 
shown to be required for mTEC maturation and Aire-expression in mTEC 
(Rossi et al. 2007, Akiyama et al. 2008, Hikosaka et al. 2008, Akiyama et al. 
2012). Our study dissecting the role of a highly conserved genomic region in 
the Aire promoter is, however, the first to provide direct evidence of the diffe-
rentiation-independent effect of the classical NF-κB pathway on Aire expression 
in mTEChi.  
We show here that in mice lacking the CNS1 the expression of Aire is 
abolished in all lymphoid tissues where Aire expression has previously been 
detected. Interestingly, CNS1 appears to serve as an immune system specific 
enhancer for both Aire and Dnmt3l as we did not see a decrease in the expres-
sion of these genes in the testis of CNS1-KO. The function of Aire in the testis 
has not been described, but in general APS1-patients and Aire-KO mice are 
subfertile (Perheentupa 2006) and this phenomenon has been attributed to auto-
immune rather than developmental effects (Kekäläinen et al. 2015). Neverthe-
less, contrary to Aire-KO, the preserved Aire expression in the testis from 
CNS1 mice makes this mouse model unique in studying the testis-specific 
activation and function of Aire. 
In addition to mediating the transcription of various TSA genes in mTEChi, 
several genes indicated in mTEC maturation, thymocyte migration and thymic 
DC migration are expressed in an Aire-dependent manner (Yano et al. 2008, 
Laan et al. 2009, Nishikawa et al. 2010, Lei et al. 2011, Wang et al. 2012). It 
has also become clear that Aire is one of the mTEC-specific factors required for 
intrathymic Treg differentiation (Malchow et al. 2013, Yang et al. 2015b, 
Malchow et al. 2016). We show that similarly to Aire-KO, mTEC in CNS1-KO 
are skewed towards the mTEChi population with elevated levels of H2-Aa and 
CD80 expression. The expression of genes inherent to terminally differentiated 
mTEC, on the other hand is decreased in CNS1-KO, indicating developmental 
block in mTEC differentiation similar to Aire-KO. Similarly, the aberrant 
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expression of Aire-dependent chemokines and TSA in mTEChi of CNS1-KO is 
close to indistinguishable from that of Aire-KO. Furthermore, both Aire-
deficient mouse strains have a reduced proportion of thymic but not splenic 
Tregs suggesting a defect in Treg development dependent on central tolerance. 
Our study in CNS1-KO did not address the peripheral autoimmune phenotype 
present in Aire-KO mice. However, another group generated CNS1-KO mice 
similar to ours and demonstrated that these mice develop infiltrates in the retina 
as well as lacrimal and salivary glands already at 14-16 weeks of age (LaFlam 
et al. 2015).  
In summary, our study identified a conserved non-coding element that is 
critical in mediating RANK-dependent upregulation of Aire in thymus and 
secondary lymphoid tissues. 
 
 
6.2.  Thymic involution during pregnancy is associated with 
changes in chemokine expression 
 
The intrathymic differentiation of developing thymocytes is tightly governed by 
contacts established with thymic stromal cells. In addition, thymic stromal cells 
produce multiple molecules required for TLP seeding, as well as further 
migration and differentiation of thymocytes (Takahama 2006). It is known that 
during pregnancy thymic involution results in a substantial drop in all thymo-
cyte populations (Tibbetts et al. 1999). What is unknown however is the role of 
thymic stromal cells in this process. Here we show that PRTI results in a 
substantial decrease in the numbers of all major thymic non-lymphoid cell 
populations. In addition, we identify the cellular sources of several key me-
diators of thymocyte maturation and migration in adult thymi and delineate the 
transcriptional changes taking place in these cell types during normal preg-
nancy. 
TLP seeding to the embryonic thymus through the CMJ relies on the 
expression of Ccr9, Cxcr4, and Ccr7. After entering the thymus, early TLP are 
recruited towards the cortex, and migrate to the medulla following positive 
selection (Takahama 2006). As we identified cTEC and fibroblasts to be the 
predominant sources for Ccl25 and Cxcl12, we suggest the cortical entry of 
TLP to rely on the expression of Ccr9 and Cxcr4 in adult thymus. Our data also 
indicates that in adult thymus mTEC direct the migration of Ccr7-expressing 
positively selected thymocytes by producing Ccl19 and Ccl21. We demonstrate 
that during PRTI the mRNA levels of all these chemokines are progressively 
decreased in their respective predominant cellular source. In addition, we show 
short-term progesterone treatment to have an impact on the expression of Ccl25 
and Cxcl12 in thymic stroma. 
Thymic involution during aging is associated with thymic stroma-specific 
changes in the transcriptional profile mediating proliferation and TLP seeding 
(Ki et al. 2014). In both ARTI and PRTI the levels of E2f3 are substantially 
decreased in TEC, resulting in a proliferative arrest of these cells. The only 
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molecule indicated in the reduced TLP seeding in ARTI is a Notch1-ligand Dll4 
(Ki et al. 2014). In late pregnancy the levels of Dll4 were reduced along with 
Kitl and IL7 all of which are required for a functional thymocyte progenitor 
niche. As the numbers of all thymic stromal subsets are decreased by late preg-
nancy, the overall reduced production of the above-listed molecules by these 
cell types is likely to be a major contributor to the reduction in TLP seeding and 
differentiating thymocyte numbers during PRTI. 
Newly generated pTregs specific for paternal antigens have a major role in 
inducing tolerance towards the developing fetus during pregnancy (Aluvihare et 
al. 2004, Samstein et al. 2012, Ruocco et al. 2014). In agreement with previous 
a report (Zoller et al. 2007) we found the proportion of bulk Foxp3+ Tregs in the 
thymus to be slightly increased by late pregnancy. However, considering the 
five-fold reduction in total Treg numbers in the thymus, this proportional 
increase is unlikely to have a major contribution to the increased numbers of 
Tregs in the peripheral blood during pregnancy (Aluvihare et al. 2004, Ruocco 
et al. 2014). These results indicate that the elevated numbers of the peripheral 
Treg pool during pregnancy derive from the increased induction and/or 
proliferation of newly induced pTregs, increased proliferation of existing tTregs 
or the combination. 
Collectively, we demonstrate that in addition to affecting TLP seeding to the 
thymus and all subsequent thymocyte populations, PRTI also results in a 
profound reduction in the cell numbers of all major thymic non-lymphoid cell 
populations. We propose that the progressive decrease of cTEC and fibroblasts 
in combination with their altered transcriptional phenotype provide a possible 
link between the effect progesterone has on TLP seeding and the developmental 
block at the DN1 stage during PRTI. 
 
 
6.3. Irf4 shapes Treg homeostasis by regulating  
the expression of thymic chemokines and  
costimulatory molecules 
 
The development of Tregs in the thymus and periphery requires a tolerogenic 
environment provided by APCs in the respective tissue or organ. Central 
tolerance induction in the thymus relies mainly on TEC, a rare and exceptional 
population of epithelial APC. However, our understanding of the transcriptional 
mechanisms rendering these cells capable of inducing tolerance in an 
autoreactive T cell is far from complete. Here we propose a model by which 
RANK-dependent activation of Irf4 and its target genes in TEC is required for 
the generation of Foxp3+ Tregs in the thymus. Thus we provide another 
example of interdependent maturation and signaling of thymocytes and TEC in 
the thymus (Anderson et al. 2007, Rossi et al. 2007, Akiyama et al. 2008, 
Hikosaka et al. 2008, Klein et al. 2014).  
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We show that the expression of Irf4 in TEC is specifically controlled by 
RANK-signaling which has been described in osteoclasts (Nakashima & Haneji 
2013) but not in the immune system. Independent of the cell-specific external 
signaling, Irf4 induction in peripheral immune cells requires NF-κB activation. 
Previous studies have mainly implicated the importance of the classical NF-κB 
pathway in Irf4 induction in peripheral APCs and lymphocytes (Grumont & 
Gerondakis 2000, Lehtonen et al. 2005). Although the extracellular stimuli 
leading to Irf4 expression differ in peripheral immune cells (Gupta et al. 1999, 
Lehtonen et al. 2005, Saito et al. 2007, Carreras et al. 2010) and TECs, results 
from our NF-κB pathway inhibition experiment also indicate the dominant role 
of the classical NF-κB pathway in Irf4 regulation in TECs. Additionally, in-
hibiting the alternative NF-κB pathway also lead to a statistically insignificant, 
although considerable reduction in Irf4 expression in TEC. Therefore the alter-
native NF-κB pathway, shown to regulate Irf4 in peripheral T cell lymphoma 
(Boddicker et al. 2015), must also be considered in TEC-specific Irf4 induction. 
TEC-specific Irf4-expression is required for the maintenance of the thymic 
Treg population, as we observed a 50% decrease in this population in our Irf4-
cKO mice. We found no significant perturbations in thymocyte differentiation 
stages prior to the CD4+ Foxp3+ T cells. Thus, we theorized Irf4 to be speci-
fically required for the function of mTEC that is the main population indicated 
in Treg differentiation. The Treg phenotype witnessed in the thymi of Irf4-cKO 
did not extend to the periphery, as we only found a slight decrease in the resting 
splenic Treg population. We found the peripheral compensation to rely on the 
increased proliferation of Tregs. Similarly to the thymic Treg population from 
mice deficient in the CNS3 of Foxp3 (Feng et al. 2015), thymic Tregs in the 
Irf4-cKO expressed higher levels of a proliferation marker Ki67 despite their 
decreased percentages. This finding indicates that although Tregs from both 
these KO-mice might be more prone to proliferate than their WT counterparts, 
mechanisms exist in the thymus that render them incapable of advancing into 
mitosis. Recently it was suggested that Tregs that recirculate back to the thymus 
inhibit de novo generation of Tregs (Thiault et al. 2015). However it is currently 
unknown whether these recirculating Tregs inhibit the induction or the 
proliferation of the already differentiated Treg cells. Either way, if intact in Irf4-
cKO this repressive mechanism might prove significant in the Treg phenotype 
witnessed in Irf4-cKO. 
Indicating that peripheral mechanisms have a dual role in the homeostatic 
compensation of splenic Treg population is the finding that Irf4-cKO mice have 
elevated levels of pTregs among CD4+ T cells. The reduced resting tTreg 
population among splenic Tregs is likely to reflect the decreased thymic output, 
as the levels of activated tTregs were unchanged in Irf4-cKO.  
Although Irf4-cKO mice have a significantly increased susceptibility to 
mononuclear infiltrations in the salivary gland, we did not find any other robust 
changes in the overall peripheral phenotype even in aged Irf4-cKO mice. This 
mild phenotype could possibly derive from Irf4 having overlapping functions 
with Irf8 or the genetic background of the C57BL/6 mice used in this study. The 
59 
increased susceptibility to salivary gland infiltrations along with the thymic 
phenotype of Irf4-cKO (skewed mTEC populations, decreased thymic Tregs) is 
reminiscent of the Aire-KO mice (Anderson et al. 2002, Malchow et al. 2013, 
Yang et al. 2015b). In addition, we found the chemokine expression profile of 
the mTEChi from both KO-mice to be similar. However, our analysis of the 
expression of mTEC maturation markers indicates, that unlike in Aire-KO, 
mTEChi in Irf4-cKO are not arrested in the mTEChi stage, as they also express 
high levels of terminally differentiated TEC markers such as Ivl and Krt6. 
Additionally, we did not find a consistent change in the expression of Aire-
dependent and -independent antigens, suggesting that the Treg phenotype in 
Irf4-cKO does not occur due to aberrations in PGE. Providing a possible 
mechanism for the decreased Treg population in the thymus is our finding that 
mTEChi from Irf-cKO express substantially decreased levels of CD40 and CD80 
mRNA when compared to WT. The changes in the expression levels of CD86, 
considered largely to be redundant with CD80, were considerably smaller.  
In conclusion, our results show that thymic Treg induction requires RANK-
dependent Irf4 expression in TEC, which in turn regulates the expression of 
several molecules indicated in Treg induction. 
 
 
6.4.  General discussion 
 
The studies included in this thesis dissect the transcriptional mechanisms that 
shape central immune tolerance in the thymus. In the first study, we demon-
strated Aire expression in mTEC to depend on an intergenic NF-κB-responsive 
enhancer element. Secondly, we delineated the effects pregnancy and 
pregnancy-related hormones impose on thymic stromal cells and how these 
effects might contribute to thymic involution during pregnancy. Lastly, we 
identified Irf4 expression in mTEC to be required for thymic Treg homeostasis. 
To emphasize how our research contributes to the studies of central tolerance 
induced in the thymus, the following section is dedicated to the connections 
between the studies and we also propose ideas for further research.  
One of the most noticeable connections we found was the similarities 
between the thymic phenotypes of mice deficient in Aire (Aire-KO and CNS1-
KO) and Irf4. For instance, the mTEChi populations in these mice have striking-
ly similar aberrations in their chemokine expression profile. In Aire-KO the 
decrease in mTEC-specific expression of Ccr4 and Ccr7 ligands results in 
delayed medullary migration of CD4+ thymocytes (Laan et al. 2009) and is 
likely to cause a similar effect in Irf4-cKO. Both these mice display decreased 
thymic Treg populations (Malchow et al. 2013, Yang et al. 2015b) (Study I, 
Study III). One of the factors determining the fate of an autoreactive thymocyte 
during negative selection is the presence of co-stimulation by surface molecules 
such as CD40 and CD80/CD86 on mTEC (Williams et al. 2014). Based on 
results presented here (Study I, Study III) and previously (Anderson et al. 
2002), Aire is required for the gene and surface expression of the TSA, whereas 
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Irf4 appears to target the genes required to provide the co-stimulation to 
differentiate the antigen-bound autoreactive thymocyte into a Treg. Thus, these 
transcription factors control distinct steps in T cell-dependent central tolerance 
induction. In this respect it would be of interest to determine the effect on the 
thymic Treg population in mice deficient in both Aire and Irf4. 
The expression of Ccr7 ligands was also perturbed in the mTEC from end-
stage pregnant mice without a substantial effect on the proportions of Th or 
Treg populations (Study II). As these mice also presented decreased expression 
of TLP-homing chemokines in cTEC and fibroblasts, the acquired mTEC-
specific chemokine expression pattern is possibly an adaptation to the overall 
decrease in the numbers of early thymocyte populations. Determining the 
transcription factors involved in the thymic stroma mediated PRTI however 
requires further research. Although it is known that all thymocyte subsets are 
decreased in PRTI, the transcriptional profile of the RANKL-producing T cells 
in pregnancy is unknown. Delineating the transcriptional networks in thymic 
crosstalk during pregnancy would expand our knowledge on what part does the 
central tolerance have in inducing and/or maintaining maternal-fetal tolerance. 
Furthermore, as PRTI and ARTI also have common phenotypic features in the 
thymic stroma, studies in this field might lead to treatments increasing thymic 
function in elderly patients suffering from various infections. In this light, it 
would be important to delineate the factors required for thymic tissue 
restoration in the mice that have recently given birth. Ex vivo administration of 
RANKL following bone marrow transfer was recently shown to boost the 
regeneration of TEC subsets and de novo thymopoiesis in mice (Lopes et al. 
2017). In TEC, the expression of both Aire and Irf4 are controlled by the 
classical NF-κB pathway, downstream of RANK-signaling (Study I, Study III), 
making them likely candidates contributing to the regeneration seen in these 
mice. However, as RANKL also induces osteoclast formation in an Irf4-
dependent manner (Nakashima & Haneji 2013), using RANKL as a treatment in 
aged patients requires stringent optimization. 
Collectively, the studies included in the current thesis broaden our general 
understanding of central tolerance mechanisms dependent on a miniscule 
epithelial compartment present in the thymus. 
 
  
61 
7. CONCLUSIONS 
 
Based on the results presented in this thesis, the following conclusions can be 
drawn 
1. The highly conserved region found in the distal promoter of the Aire gene is 
a critical transcriptional regulator of Aire expression in vivo. The deletion of 
this region results in a thymic phenotype identical with that of Aire-KO 
mice. 
2. PRTI results in a substantial decrease in the total numbers of all thymic 
non-lymphoid cell types with significant changes in their proportions within 
thymic stroma. This decrease is accompanied by changes in the tran-
scriptional patterns of these cells. Most importantly, the cells responsible 
for TLP seeding downregulate the expression of molecules required for the 
homing and early differentiation of thymocyte progenitors. 
3. Irf4 acts as a critical transcriptional regulator in murine TEC. In addition to 
controlling mTEC differentiation, it activates the transcription of several 
chemokines and costimulatory molecules critical for central tolerance 
dependent Treg induction. 
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8. SUMMARY IN ESTONIAN 
 
Tsentraalse tolerantsuse eest vastutavad transkriptsioonilised 
protsessid tüümuses  
  
Immuunsüsteemi toimimise üheks peamiseks alustalaks on võime eristada pato-
geenidest pärinevaid antigeene kehaomastest või ka organismile ohtu mitte ku-
jutavatest võõrantigeenidest. Selle eristusvõime tagavad immuuntolerantsuse 
mehhanismid, mis jagatakse tolerantsust indutseeriva keskkonna põhjal kaheks: 
tsentraalne ja perifeerne immuuntolerantsus. Tsentraalse immuuntolerantsuse 
kujunemise kohaks on primaarsed lümfoidorganid; tüümus ja luuüdi. T-rakuline 
immuuntolerantsus kujuneb välja tüümuses, kus T-rakkude eellased (tümo-
tsüüdid) läbivad nö „koolitusprogrammi“ ehk selektsiooni, mille käigus elimi-
neeritakse apoptoosi teel need T-rakud, mis reageerivad kehaomastele anti-
geenidele ja võiksid põhjustada autoimmuunvastust omaenda kudede vastu. 
Teise võimalusena suunatakse autoimmuunsed T-rakud supresseeriva funkt-
siooniga rakkudeks – regulatoorseteks T rakkudeks (Treg).  
Oluliseks rakutüübiks tüümuses toimuva selektsiooniprotsessi tagamisel on 
tüümuse epiteelirakud, mis asetsevad organi koore- ja säsiosas ja tüümuse dend-
riitrakud. Selektsiooniprotsessi käigus moodustavad T-rakud rakk-rakk kontakte 
tüümuse epiteeli- ja dendriitrakkudega. Rakkudevahelised kontaktid tüümuse 
kooreosa epiteeliga määravad tümotsüütide arengu varasemad etapid, samas kui 
kontaktid tüümuse säsiosa epiteeliga on olulised autoimmuunsete tümotsüütide 
selekteerimiseks. Tüümuse epiteelirakud tagavad autoimmuunsete tümotsüütide 
selekteerimise selle kaudu, et nad ekspresseerivad suurt osa organismi koe-
spetsiifilistest geenidest. Nende geenide poolt kodeeritud valkudest pärinevaid 
peptiide esitletakse epiteeli raku pinnal koesobivusantigeenide (MHC; major 
histocompatibility complex) poolt arenevatele tümotsüütidele. Autoimmuunse 
potentsiaaliga tümotsüütides käivituvad seejärel signaalirajad, mis suunavad need 
rakud apoptoosi või diferentseeritakse nad Treg rakkudeks. Kuna ka Treg rakkude 
funktsioon organismis on autoimmuunsete reaktsioonide ärahoidmine, siis 
toetavad mõlemad mehhanismid immuuntolerantsuse kujunemist.  
Laialdase avatud geeniekspressiooni eest tüümuse säsiepiteelis vastutab valk 
nimega Autoimmuunsuse Regulaator (AIRE, hiires vastavalt Aire). AIRE-geenil 
on väga spetsiifiline avaldumise muster olles kõige kõrgemalt ekspresseerunud 
tüümuse epiteelis. Samas on seni olnud teadmata, kuidas reguleeritakse AIRE-geeni 
spetsiifilist ekspressiooni. See teema moodustab antud väitekirja esimese artikli. 
Väitekirja teine osa käsitleb tüümuses toimuvaid geeni avaldumise muutusi hiire 
tiinuse käigus. Areneval lootel on pooled geenid päritud isalt ja seega on loode ema 
immuunsüsteemi jaoks osaliselt võõrsiirik. Seega eeldab loote normaalne arene-
mine muutusi ema immuuntolerantsuse mehhanismides. Varasemast on teada, et 
nii tiinuse kui ka vananemise korral väheneb märgatavalt tüümuse maht ehk toi-
mub tüümuse involutsioon. Samas ei ole seni uuritud tiinuse jooksul toimuvaid 
muutusi geenide avaldumises tüümuse epiteelis. Kolmandas osatöös on uuritud 
transkriptsioonifaktor Irf4 mõju tüümuse epiteelile ja Tregide diferentseerumisele. 
63 
Uurimistöö eesmärgid 
 
1. Iseloomustada Aire-geeni oletatavas enhaanserjärjestuses asuvat evolutsioo-
niliselt konserveerunud regulaatorala funktsioon. 
2. Uurida tiinusega seotud tüümuse involutsioonis toimuvaid muutusi erine-
vates tüümuse rakupopulatsioonides ning määrata tiinuse mõju nende 
rakkude geeniekspressioonile. 
3. Määrata Irf4 transkriptsioonifaktori roll tüümuse epiteeli arengus ja tsent-
raalse tolerantsuse indutseerimisel. 
 
Uurimistöö peamised tulemused ja järeldused 
 
Esimese töö eesmärk oli uurida Aire ekspressiooni reguleeriva enhaanseri funkt-
siooni. Eesmärgi täitmiseks aretati Tartu Ülikooli Katseloomakeskuses geen-
modifitseeritud hiireliin, mille genoomist puudus oletatavast enhaanserjärjes-
tusest 45-aluspaari pikkune DNA-lõik. Oma töös andsime antud piirkonnale 
nimeks konserveerunud mittekodeeriv järjestus 1 (CNS1; conserved noncoding 
sequence). Enhaanserala olulisuse määramiseks Aire geeni regulatsioonis ana-
lüüsisime reaalaja-PCRi abil CNS1-puudulikest (CNS1-KO) ja metsiktüüpi 
hiirte tüümusest, põrnast, lümfisõlmedest ja munanditest eraldatud mRNA baa-
sil sünteesitud cDNAst Aire transkripti olemasolu. Kõigis CNS1-KO hiire kude-
des, va munandites oli Aire ekspressioon oluliselt madalam kui metsiktüüpi 
hiire vastavates kudedes. Edasised voolutsütomeetrial ning immuunfluorestsent-
sil põhinevad meetodid kinnitasid, et CNS1-KO hiired ei ekspresseeri tüümuses 
ka Aire valku. Lisaks kinnitas FACSi meetodil (fluorescence-activated cell-
sorting) sorditud tüümuse epiteeli rakkudele tehtud reaalaja-PCRi analüüs, et 
sarnaselt Aire-KO hiirele on CNS1-KO hiire tüümuse epiteelis häirunud avatud 
geeniekspressioon. Täheldasime ka muutusi säsi epiteelirakkude diferentsee-
rumises ja nende rakkude poolt vahendatavas kemokiinide ekspressioonis. 
Tümotsüütide voolutsütoomeetriline analüüs tuvastas ka, et sarnaselt Aire-KO 
hiirega on CNS1-KO hiire tüümuses oluliselt vähem Treg rakke. Kokkuvõtvalt 
võib öelda, et CNS1 piirkond on keskne Aire geeni avaldumiseks tüümuse 
epiteelis ning et Aire-puuduliku fenotüübi tekitamiseks piisas CNS1-piirkonna 
eemaldamisest hiire genoomist. 
Teise eesmärgi saavutamine eeldas erinevate tüümuse rakupopulatsioonide 
isoleerimist kontrollhiirtest ja kolmes erineva tiinuse staadiumis olevatest hiir-
test (1.–3. trimester). Tümotsüütide voolutsütomeetriline analüüs kinnitas vara-
semaid tulemusi, mille kohaselt väheneb tiinuse käigus kõigi tümotsüütide ala-
populatsioonide arvukus. Uue leiuna kirjeldasime rasedusaegse involutsiooni 
mõju tüümuse epiteeli rakkudele ja nende omavahelistele proportsionaalsetele 
suhetele. Tuvastasime, et tüümuse epiteeli rakkude arvukus väheneb sarnaselt 
tümotsüütidele ja kolmandaks trimestriks on oluliselt muutunud ka epiteeli 
rakkude alapopulatsioonide omavaheline suhe. Leidsime, et rasedus/tiinus mõ-
jutab suurel määral tüümuse epiteeli alapopulatsioonide geeniekspressiooni pro-
fiili. Geenide hulgas, mille ekspressioon oli vähenenud, oli mitmeid kemokiine 
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ja faktoreid, mis meelitavad T-rakkude eellasi tüümusesse ja koordineerivad 
nende migratsiooni ja diferentseerumist tüümuse koore- ja säsiosas. Lisaks 
tiinusele toimub sarnane tüümuse involutsioon ka vananemise ajal. Vanane-
misest tulenevat tüümuse koe kadu ja sellega kaasnevat tüümuse funktsiooni 
langust peetakse üheks eakatel inimestel esinevate nakkushaiguste raske kulu 
põhjuseks. Leidsime, et kahel nii erineval füsioloogilisel põhjusel toimuvatel 
muutustel tüümuses on mitmeid ühiseid jooni tüümuse epiteeli geenide avaldu-
mises. Seega võiksid antud töös kirjeldatud mehhanismid lisaks rasedusaegse 
immuuntolerantsuse muudatuste kirjeldamisele aidata mõista ja mõjutada ka 
tüümuse aktiivsuse langust eakatel patsientidel.   
Kolmanda eesmärgi saavutamiseks ristasime omavahel geneetiliselt muun-
datud hiiri, mille tulemusel saime katseloomad, kellel puudus tüümuse epiteeli-
rakkudes funktsionaalne Irf4-geen. Neis katseloomades, kelle tüümuse epiteelis 
Irf4-geenilt valku ei kodeeritud, tuvastasime mitmeid immunoloogilisi kõrvale-
kaldeid metsiktüüpi hiirtest. Ühe peamise leiuna avastasime, et nende hiirte tüü-
mustes on Tregide populatsioon vähenenud kaks korda. Kuna Treg rakkude 
osakaal on oluline immuuntolerantsuse kujunemises, viitab selline muutus 
võimalikule autoimmuunsele protsessile ning näitab Irf4 tähtsust autoimmuun-
vastuse vältimises. Võimaliku autoimmuunse reaktsiooniga kooskõlas leidsime 
neis hiirtes immuunrakkude infiltratsioone süljenäärmes. Töös otsisime ka põh-
jusi, miks on neis hiirtes vähem Treg rakke. Geeniekspressiooni analüüsiga tu-
vastasime FACSi meetodil sorditud tüümuse epiteelist, et Irf4-puudulikes 
rakkudes on metsiktüüpi hiire rakkudega võrreldes oluliselt langenud mitmete 
Treg rakkude diferentseerumiseks vajalike kemokiinide ja kostimulatoorsete 
molekulide ekspressioon. Seega on Irf4 Aire kõrval üks väheseid teadaolevaid 
transkriptsioonifaktoreid, mille ekspressioon tüümuse epiteelis on vajalik Treg 
rakkudest sõltuva tsentraalse tolerantsuse tekitamiseks. 
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